

附录A 编制方法与策略(资料性)

Appendix A Compilation methods and strategies (informative)

1.1 编制方法 本文件的设计与制定参考了2014年发布的《世界卫生组织指南制定手册》中关于指南的制订流程以及方法学标准,并参考指南研究与评价工具(Appraisal of Guidelines for Research and Evaluation, AGREE II)和《中医药临床实践指南质量评价建议清单及解读》进行编写。首先征集临床医生关心的问题,然后运用《基于证据体的中医药临床证据分级标准建议》中的方法对证据体进行评价与分级,参考GRADE(Grading of Recommendations, Assessment, Development and Evaluation)体系得出推荐意见,最终由共识小组专家投票达成共识,具体编制流程见图1。

1.2 证据检索策略 选用数据库包括中国知网(CNKI)、中国生物医学文献数据库(China Biology Medicine disc, CBMdisc)、维普(VIP data)、万方(Wanfang data)、Pubmed、Cochrane、Embase。有主题词标引数据库采用主题词与自由词联合检索,无主题词标引数据库采用高级检索/专业检索、主题检索。

1.3 数据的筛选和提取 数据的筛选和提取由两位研究者共同进行,在筛选前对两位研究者进行规范化培训和校准,然后按照纳排标准独立阅读文献的标题和摘要,筛选潜在的合格试验。如果意见不一致,通过讨论统一意见,或交由第三方评价。

文献筛选过程在NoteExpress V3.0中进行,资料提取表主要包括:研究的基本情况(作者、研究题目、出版年月、国家/地区)、研究特征(样本量、病例来源、受试者年龄、诊断标准、纳排标准、辨证分型)、试验组和对照组的干预措施(剂型、剂量和持续时间)、中医外治法(具体穴位、操作手法、穴位贴敷具体药物)、文献质量评价指标(随机方案生成、隐藏分配、盲法、不完整的结果数据、选择性报道、其他偏差、失访)和结局指标。文献筛选流程详见图2。

1.4 证据质量评价与分级 两位研究者参照《基于证据体的中医药临床证据分级标准建议》对纳入的有效性和安全性的证据体进行汇总和质量评价。根据中医药临床研究证据的分级标准,将证据级别分为I、II、III、IV、V级5个等级(表1)。

系统综述质量评价过程中考虑以下8个降级因素(表2);随机对照试验(RCT)证据质量评价过程中考虑以下6个降级因素(表3)。




图1 指南编制流程图

Figure 1 Flow chart for the compilation of guidelines

1.5 推荐意见强度的定义 参照GRADE体系^[206]对推荐意见进行强度分级,得到初步的推荐意见,见表4。

1.6 形成推荐意见的方法 本文件形成推荐意见采用会议共识法,共邀请临床专家27名、方法学专家1名、药学专家1名。会议采用名义小组法进行专家投票。本次会议共进行了三轮的投票,第一轮专家投票达成共识43条、未达成共识3条,第二轮专家投票达成共识1条、未达成共识2条,第三轮专家投票达成共识2条、未达成共识0条。




图2 文献筛选流程图

Figure 2 Flow chart for literature screening

表1 证据分级

Table 1 Levels of evidence

| 证据等级 | 内容 |
|------|-----------------------------|
| I级 | 随机对照试验及其系统综述、单个病例随机对照试验系统综述 |
| II级 | 非随机临床对照试验、队列研究、单个病例随机对照试验 |
| III级 | 病例对照研究、前瞻性病例系列 |
| IV级 | 规范化的专家共识、回顾性病例系列、历史性对照研究 |
| V级 | 非规范化专家共识、病例报告、经验总结 |

表2 系统综述质量评价

Table 2 Quality assessment of systematic reviews

| 序号 | 降级因素 |
|----|---------------------------|
| a | 有明确的临床问题,并正确按照PICO原则进行结构化 |
| b | 纳入标准恰当 |
| c | 纳入研究的选择和数据提取具有可重复性 |
| d | 检索全面、提供了明确的检索策略 |
| e | 描述纳入研究的特征 |
| f | 评价和报道了纳入研究的方法学质量 |
| g | 数据综合方法正确 |
| h | 无相关利益冲突 |

表3 RCT证据质量评价

Table 3 Quality assessment of RCT evidence

| 序号 | 降级因素 |
|----|---------|
| a | 随机序列的产生 |
| b | 随机化隐藏 |
| c | 盲法 |
| d | 不完整结局报告 |
| e | 选择性报告结局 |
| f | 样本含量 |

表4 GRADE系统推荐强度等级

Table 4 Strength of recommendation based on the GRADE system

| 推荐强度 | 具体描述 |
|------|------------------------|
| 强推荐 | 明确显示干预措施利大于弊或者弊大于利 |
| 弱推荐 | 利弊不确定或无论质量高低的证据均显示利弊相当 |

附录B 指南问题汇总(资料性)

Appendix B A Summary of problems in the guideline (informative)

指南制作小组成员通过组内讨论、问卷调查及名义小组法专家共识法确定了13个重要的临床问题,并确定每个临床问题对应的研究对象、干预措施、对照措施及

结局指标 (participant, intervention, comparison and outcome; PICO),见表5。

表5 临床问题列表

Table 5 A list of clinical problems

| 序号 | 临床问题 |
|----|--|
| 1 | 中医药治疗联合外科手术治疗原发性肝癌较单独外科手术治疗临床疗效是否更好? |
| 2 | 中医药治疗联合常规西药治疗原发性肝癌术后并发症较常规西药治疗临床疗效是否更好? |
| 3 | 中医药治疗联合常规西药预防原发性肝癌根治术后复发较常规西药预防临床疗效是否更好? |
| 4 | 中医药治疗联合TACE/消融治疗原发性肝癌较单独TACE/消融治疗临床疗效是否更好? |
| 5 | 中医药治疗联合常规西药治疗介入后栓塞综合征较单独常规西药治疗临床疗效是否更好? |
| 6 | 中医药治疗联合放疗治疗原发性肝癌较单独放疗治疗临床疗效是否更好? |
| 7 | 中医药治疗联合化疗治疗原发性肝癌较单独化疗治疗临床疗效是否更好? |
| 8 | 中医药治疗联合靶向/免疫治疗原发性肝癌较单独靶向治疗临床疗效是否更好? |
| 9 | 中医药治疗联合常规西药治疗靶向/免疫药物不良反应较单独常规西药治疗临床疗效是否更好? |
| 10 | 中医药治疗联合常规西药治疗原发性肝癌腹水较单独常规西药治疗临床疗效是否更好? |
| 11 | 中医药治疗联合常规西药治疗原发性肝癌癌性发热较单独常规西药治疗临床疗效是否更好? |
| 12 | 中医药治疗联合常规西药治疗原发性肝癌癌性疲乏较单独常规西药治疗临床疗效是否更好? |
| 13 | 中医药治疗联合常规西药治疗原发性肝癌癌性疼痛较单独常规西药治疗临床疗效是否更好? |

附录C 中成药证据汇总表(资料性)

Appendix C A Summary of evidence for Chinese patent drugs (informative)

表6 外科切除术后中成药辨证治疗

Table 6 Syndrome differentiation-based treatment with Chinese patent drugs after surgical resection

| 中成药 | 降低术后复发率,延长生存期 | 调节机体免疫功能 | 改善术后不良反应 | 改善术后患者生活质量 |
|-------------|---------------|----------|----------|------------|
| 槐耳颗粒 | I级,强推荐 | 无 | 无 | 无 |
| 金龙胶囊 | II级,强推荐 | II级,强推荐 | 无 | II级,强推荐 |
| 华蟾素片/胶囊/注射液 | II级,强推荐 | II级,强推荐 | 无 | 无 |
| 复方苦参注射液 | III级,弱推荐 | III级,弱推荐 | III级,弱推荐 | 无 |
| 参芪扶正注射液 | 无 | II级,强推荐 | II级,强推荐 | 无 |
| 生脉注射液 | 无 | 无 | III级,强推荐 | 无 |

表7 TACE/消融联合中成药辨证治疗

Table 7 TACE/ablation combined with syndrome differentiation-based treatment with Chinese patent drugs

| 中成药 | 提高客观有效率 | 延长生存期 | 改善术后患者生活质量 | 增强机体免疫力 | 改善术后不良反应 | 改善栓塞后综合征 |
|----------------------------|---------|--------|------------|---------|----------|----------|
| 槐耳颗粒 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 | 无 | 无 |
| 金龙胶囊 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | 无 |
| 华蟾素片/胶囊/注射液 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 | 无 |
| 复方苦参注射液 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 | 无 |
| 参芪扶正注射液 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | 无 |
| 榄香烯乳剂/注射液 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | 无 | 无 | Ⅱ级,强推荐 | 无 |
| 回生口服液 | Ⅱ级,弱推荐 | 无 | Ⅱ级,弱推荐 | 无 | 无 | 无 |
| 消癌平/通关藤注射液 | Ⅱ级,弱推荐 | 无 | Ⅱ级,弱推荐 | 无 | Ⅱ级,弱推荐 | 无 |
| 艾迪注射液 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 | Ⅲ级,弱推荐 | Ⅱ级,弱推荐 | 无 |
| 鸦胆子油乳 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 | 无 | Ⅱ级,弱推荐 | 无 |
| 康艾注射液 | Ⅱ级,强推荐 | 无 | 无 | Ⅱ级,强推荐 | 无 | Ⅲ级,弱推荐 |
| 肝复乐胶囊/片 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | 无 | 无 | 无 | 无 |
| 康莱特注射液 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 | 无 | 无 | 无 |
| 慈丹胶囊 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 | 无 | 无 | 无 | 无 |
| 斑蝥酸钠维生素 B ₆ 注射液 | 无 | Ⅲ级,强推荐 | 无 | 无 | 无 | 无 |
| 血必净注射液 | 无 | 无 | 无 | 无 | 无 | Ⅱ级,强推荐 |
| 清开灵注射液 | 无 | 无 | 无 | 无 | 无 | Ⅲ级,弱推荐 |
| 复方叶下珠颗粒剂 | 无 | 无 | 无 | 无 | 无 | Ⅲ级,弱推荐 |
| 八宝丹胶囊 | 无 | 无 | 无 | 无 | 无 | Ⅲ级,弱推荐 |
| 西黄胶囊 | 无 | 无 | 无 | 无 | 无 | Ⅲ级,弱推荐 |
| 养正消积胶囊 | Ⅱ级,强推荐 | 无 | 无 | Ⅱ级,强推荐 | 无 | Ⅲ级,弱推荐 |

表8 放疗联合中成药辨证治疗

Table 8 Radiotherapy combined with syndrome differentiation-based treatment with Chinese patent drugs

| 中成药 | 提高放疗后抗肿瘤有效率 | 延长生存期 | 提高生活质量 | 增强机体免疫力 | 降低复发、转移率 | 改善不良反应 |
|----------------------------|-------------|--------|--------|---------|----------|--------|
| 槐耳颗粒 | Ⅲ级,强推荐 | Ⅲ级,强推荐 | 无 | 无 | 无 | 无 |
| 金龙胶囊 | Ⅱ级,强推荐 | 无 | 无 | 无 | 无 | 无 |
| 艾迪注射液 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 | 无 | 无 |
| 康艾注射液 | Ⅲ级,弱推荐 | 无 | Ⅲ级,弱推荐 | 无 | Ⅲ级,弱推荐 | Ⅲ级,弱推荐 |
| 康莱特注射液 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 |
| 斑蝥酸钠维生素 B ₆ 注射液 | 无 | Ⅲ级,弱推荐 | Ⅲ级,弱推荐 | 无 | 无 | 无 |
| 复方斑蝥胶囊 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 |
| 复方丹参注射液 | Ⅱ级,弱推荐 | 无 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 | 无 | 无 |
| 去甲斑蝥酸钠 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 |
| 片仔癀 | 无 | Ⅲ级,强推荐 | 无 | 无 | 无 | Ⅲ级,强推荐 |

表9 化疗联合中成药辨证治疗

Table 9 Chemotherapy combined with syndrome differentiation-based treatment with Chinese patent drugs

| 中成药 | 提高化疗抗肿瘤有效率 | 延长生存期 | 提高生活质量 | 改善肝功能异常 | 增强机体免疫力 | 改善不良反应 |
|-------------|------------|--------|--------|---------|---------|--------|
| 槐耳颗粒 | 无 | 无 | Ⅱ级,强推荐 | 无 | 无 | 无 |
| 华蟾素片/胶囊/注射液 | 无 | 无 | Ⅲ级,强推荐 | 无 | 无 | Ⅲ级,强推荐 |
| 艾迪注射液 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 | Ⅱ级,强推荐 |
| 鸦胆子油乳 | 无 | 无 | Ⅲ级,弱推荐 | Ⅲ级,弱推荐 | 无 | 无 |
| 康艾注射液 | Ⅱ级,弱推荐 | 无 | Ⅱ级,弱推荐 | 无 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 |
| 康莱特注射液 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | 无 | 无 | Ⅱ级,强推荐 | Ⅱ级,强推荐 |
| 慈丹胶囊 | Ⅲ级,强推荐 | 无 | Ⅲ级,强推荐 | 无 | Ⅲ级,强推荐 | Ⅲ级,强推荐 |
| 复方斑蝥胶囊 | 无 | 无 | 无 | Ⅲ级,强推荐 | Ⅲ级,强推荐 | 无 |
| 参麦注射液 | Ⅲ级,强推荐 | 无 | Ⅲ级,强推荐 | 无 | Ⅲ级,强推荐 | Ⅲ级,强推荐 |
| 大黄廬虫丸 | Ⅲ级,弱推荐 | Ⅲ级,弱推荐 | Ⅲ级,弱推荐 | 无 | Ⅲ级,强推荐 | Ⅲ级,弱推荐 |
| 消癥益肝片 | 无 | 无 | 无 | 无 | Ⅲ级,弱推荐 | 无 |
| 复方苦参注射液 | Ⅱ级,弱推荐 | 无 | 无 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 |
| 参芪扶正注射液 | 无 | 无 | Ⅲ级,弱推荐 | 无 | 无 | Ⅲ级,弱推荐 |

表10 靶向/免疫治疗联合中成药辨证治疗

Table 10 Targeted therapy/immunotherapy combined with syndrome differentiation-based treatment with Chinese patent drugs

| 中成药 | 提高靶免抗肿瘤有效率 | 延长生存期 | 提高生活质量 | 改善肝功能异常 | 增强机体免疫力 | 改善不良反应 |
|------------|------------|--------|--------|---------|---------|--------|
| 槐耳颗粒 | Ⅲ级,弱推荐 | Ⅲ级,弱推荐 | Ⅲ级,弱推荐 | 无 | 无 | Ⅲ级,弱推荐 |
| 华蟾素片/胶囊注射液 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 | 无 | 无 | 无 |
| 参芪扶正注射液 | 无 | 无 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | Ⅱ级,强推荐 |
| 榄香烯乳剂/注射液 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 | 无 | 无 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 |
| 槐耳颗粒 | Ⅲ级,弱推荐 | Ⅲ级,弱推荐 | Ⅲ级,弱推荐 | 无 | 无 | Ⅲ级,弱推荐 |
| 华蟾素片/胶囊注射液 | Ⅱ级,强推荐 | 无 | Ⅱ级,强推荐 | 无 | 无 | 无 |
| 参芪扶正注射液 | 无 | 无 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | Ⅱ级,强推荐 | Ⅱ级,强推荐 |
| 榄香烯乳剂/注射液 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 | 无 | 无 | Ⅱ级,弱推荐 | Ⅱ级,弱推荐 |

表11 并发症中成药辨证治疗

Table 11 Complications associated with syndrome differentiation-based treatment with Chinese patent drugs

| 中成药 | 改善癌性腹水 | 改善癌性疲乏 | 改善癌性疼痛 |
|------------|--------|--------|--------|
| 华蟾素片/胶囊注射液 | 无 | 无 | Ⅲ级,弱推荐 |
| 复方苦参注射液 | Ⅱ级,弱推荐 | 无 | 无 |
| 榄香烯乳剂/注射液 | Ⅱ级,弱推荐 | 无 | 无 |
| 艾迪注射液 | Ⅱ级,强推荐 | 无 | 无 |
| 康艾注射液 | Ⅱ级,弱推荐 | Ⅲ级,弱推荐 | 无 |

参考文献:

- [1] ZHOU MG, WANG HD, ZENG XY, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.
- [2] CHEN WQ, ZHENG RS, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA A Cancer J Clinicians, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
- [3] General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition) [J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
- 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝

胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

- [4] State Administration for Market Regulation, China National Standardization Administration. Directives for standardization—Part 1: Rules for the structure and drafting of standardizing documents: GB/T 1.1-2020[S/OL]. (2020-03-31) [2024-04-19]. <http://c.gb688.cn/bzgk/gb/showGb?type=online&hcno=C4BFD981E993C417EF475F2A19B681F1>.
- 国家市场监督管理总局, 中国国家标准化管理委员会. 标准化工作导则第1部分: 标准化文件的结构和起草规则: GB/T 1.1-2020[S/OL]. (2020-03-31) [2024-04-19]. <http://c.gb688.cn/bzgk/gb/showGb?type=online&hcno=C4BFD981E993C417EF475F2A19B681F1>.
- [5] State Administration for Market Regulation, China National Standardization Administration. Clinic terminology of traditional Chinese medi-

- cal diagnosis and treatment—Part 1:Diseases: GB/T 16751.1—2023 [S/OL]. (2023-03-17) [2024-04-19]. <http://c.gb688.cn/bzgk/gb/showGb?type=online&hcno=7377FB06FF43DC321BB6A4BF7DAA7F39>.
- 国家市场监督管理总局, 中国国家标准化管理委员会. 中医临床诊疗术语 第1部分: 疾病: GB/T 16751.1—2023[S/OL]. (2023-03-17) [2024-04-19]. <http://c.gb688.cn/bzgk/gb/showGb?type=online&hcno=7377FB06FF43DC321BB6A4BF7DAA7F39>.
- [6] State Administration for Market Regulation, China National Standardization Administration. Clinic terminology of traditional Chinese medical diagnosis and treatment—Part 2: Syndromes/patterns: GB/T 16751.2-2021[S/OL]. (2021-11-26) [2024-04-19]. <https://openstd.samr.gov.cn/bzgk/gb/newGbInfo?hcno=C71A9DAD24CB1252F12439D1F045DA6A>.
- 国家市场监督管理总局, 中国国家标准化管理委员会. 中医临床诊疗术语 第2部分: 证候: GB/T 16751.2-2021[S/OL]. (2021-11-26) [2024-04-19]. <https://openstd.samr.gov.cn/bzgk/gb/newGbInfo?hcno=C71A9DAD24CB1252F12439D1F045DA6A>.
- [7] State Administration for Market Regulation, China National Standardization Administration. Classification and codes of diseases and patterns of traditional Chinese medicine: GB/T 15657—2021[S/OL]. (2021-10-11) [2024-04-19]. <https://openstd.samr.gov.cn/bzgk/gb/newGbInfo?hcno=41FD9D06E5BE4F84EA1D8D07101BED2C>.
- 国家市场监督管理总局, 中国国家标准化管理委员会. 中医证证分类与代码: GB/T 15657—2021[S/OL]. (2021-10-11) [2024-04-19]. <https://openstd.samr.gov.cn/bzgk/gb/newGbInfo?hcno=41FD9D06E5BE4F84EA1D8D07101BED2C>.
- [8] General Administration of Quality Supervision, Inspection and Quarantine of the People's Republic of China, National Standardization Administration of China. Information and documentation—Rules for bibliographic references and citations to information resources[S/OL]. (2015-05-15) [2024-04-19]. <https://openstd.samr.gov.cn/bzgk/gb/newGbInfo?hcno=7FA63E9BBA56E60471AEDAEBDE44B14C>.
- 国家市场监督管理总局, 中国国家标准化管理委员会. 信息与文献 参考文献著录规则: GB/T 7714—2015[S/OL]. (2015-05-15) [2024-04-19]. <https://openstd.samr.gov.cn/bzgk/gb/newGbInfo?hcno=7FA63E9BBA56E60471AEDAEBDE44B14C>.
- [9] WANG DF. A Study on the historical origins and related treatment of liver accumulation[D]. Xianyang: Shaanxi University of Chinese Medicine, 2017.
- 王栋飞. 对肝积历史源流及其相关证治的研究[D]. 咸阳: 陕西中医药大学, 2017.
- [10] Clinical Guidelines Committee of Chinese Interventionalists College. Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma[J]. Chin J Intern Med, 2021, 60(7): 599-614. DOI: 10.3760/cma.j.cn112137-20210425-00991.
- 中国医师协会介入医师分会临床诊疗指南专委会. 中国肝细胞癌经动脉化疗栓塞(TACE)治疗临床实践指南(2021年版)[J]. 中华内科杂志, 2021, 60(7): 599-614. DOI: 10.3760/cma.j.cn112137-20210425-00991.
- [11] National Major and Difficult Diseases (Primary Liver Cancer) Clinical Cooperation Group of Traditional Chinese and Western Medicine. Consensus on Diagnosis and Treatment of Primary Liver Cancer with Integrated Traditional Chinese and Western Medicine[J]. Chin Med Herald, 2021, 27(9): 101-107. DOI: 10.13862/j.cnki.cn43-1446/r.2021.09.030.
- 国家重大疑难疾病(原发性肝癌)中西医临床协作组. 原发性肝癌中西医结合诊疗专家共识[J]. 中医药导报, 2021, 27(9): 101-107. DOI: 10.13862/j.cnki.cn43-1446/r.2021.09.030.
- [12] Chinese Society of Traditional Chinese Medicine. Guidelines for Traditional Chinese Medicine Diagnosis and Treatment of Tumors: ZYYXH/T 136-156-2008 [S]. Beijing: China Press of Traditional Chinese Medicine, 2008.
- 中华中医药学会. 肿瘤中医诊疗指南: ZYYXH/T 136 ~ 156—2008[S].
- 北京: 中国中医药出版社, 2008.
- [13] LIN HS. Guidelines of diagnosis and therapy in oncology with traditional Chinese medicine[M]. Beijing: People's Medical Publishing House, 2014.
- 林洪生. 恶性肿瘤中医诊疗指南[M]. 北京: 人民卫生出版社, 2014.
- [14] Chinese Association of Integrated Traditional Chinese and Western Medicine, Chinese Society of Traditional Chinese Medicine, Chinese Medical Association. Guidelines for the Diagnosis and Treatment of Primary Liver Cancer with Integrated Traditional Chinese and Western Medicine[EB/OL]. (2023-05-31) [2024-04-19]. <https://www.cacm.org.cn/wp-content/uploads/2023/06/%E5%8E%9F%E5%8F%91%E6%80%A7%E8%82%9D%E7%99%8C%E4%B8%AD%E8%A5%BF%E5%8C%BB%E7%BB%93%E5%90%88%E8%AF%8A%E7%96%97%E6%8C%87%E5%8D%97.pdf>.
- 中国中西医结合学会, 中华中医药学会, 中华医学会. 原发性肝癌中西医结合诊疗指南[EB/OL]. (2023-05-31) [2024-04-19]. <https://www.cacm.org.cn/wp-content/uploads/2023/06/%E5%8E%9F%E5%8F%91%E6%80%A7%E8%82%9D%E7%99%8C%E4%B8%AD%E8%A5%BF%E5%8C%BB%E7%BB%93%E5%90%88%E8%AF%8A%E7%96%97%E6%8C%87%E5%8D%97.pdf>.
- [15] THERASSE P, ARBUCK SG, EISENHAEUER EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000, 92(3): 205-216. DOI: 10.1093/jnci/92.3.205.
- [16] LENCIONI R, LLOVET JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60. DOI: 10.1055/s-0030-1247132.
- [17] CHENG RW, LI P, DENG LP. Effect of TACE combined with Chaihu Shugan Powder on hepatocellular carcinoma of liver depression and spleen deficiency[J]. Guid J Tradit Chin Med Pharm, 2016, 22(20): 20-23. DOI: 10.13862/j.cnki.cn43-1446/r.2016.20.007.
- 程瑞文, 李平, 邓梨平. TACE序贯柴胡疏肝散治疗肝郁脾虚型肝癌的临床研究[J]. 中医药导报, 2016, 22(20): 20-23. DOI: 10.13862/j.cnki.cn43-1446/r.2016.20.007.
- [18] ZHANG GP. Clinical observation on TACE combined with Chinese medicine in the treatment of primary liver cancer complicated with portal vein tumor Thrombus[J]. Chin Med Mod Distance Educ China, 2022, 20(10): 59-61. DOI: 10.3969/j.issn.1672-2779.2022.10.022.
- 张国平. TACE联合中药治疗原发性肝癌伴门静脉癌栓临床观察[J]. 中国中医药现代远程教育, 2022, 20(10): 59-61. DOI: 10.3969/j.issn.1672-2779.2022.10.022.
- [19] WU Y. Clinical efficacy of chaihu shugan powder in the treatment of liver qi stagnation after intervention of hepatocellular carcinoma[D]. Harbin: Heilongjiang University of Chinese Medicine, 2019.
- 吴杨. 柴胡疏肝散加减治疗肝癌介入术后肝气郁结型患者的临床疗效观察[D]. 哈尔滨: 黑龙江中医药大学, 2019.
- [20] YAN TF, CAO ZQ, YAO SS, et al. Clinical observation of Chaihu Shugan Powder combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer[J]. World J Integr Tradit West Med, 2021, 16(7): 1357-1361. DOI: 10.13935/j.cnki.sjzx.210737.
- 燕腾飞, 曹志群, 姚姗姗, 等. 柴胡疏肝散加减联合动脉化疗栓塞术治疗原发性肝癌的临床观察[J]. 世界中西医结合杂志, 2021, 16(7): 1357-1361. DOI: 10.13935/j.cnki.sjzx.210737.
- [21] WU MH, ZHOU YF, CHEN XF, et al. Chaihushugansan in combination with fentanyl transdermal system as therapy in pain of liver cancer patients[J]. Chin J Integr Tradit West Med Liver Dis, 2013, 23(2): 83-85. DOI: 10.3969/j.issn.1005-0264.2013.02.006.
- 吴敏华, 周月芬, 陈旭烽, 等. 柴胡疏肝散辅助芬太尼透皮贴治疗肝癌疼痛[J]. 中西医结合肝病杂志, 2013, 23(2): 83-85. DOI: 10.3969/j.issn.1005-0264.2013.02.006.

- [22] LU DY, YE XW. Clinical efficacy of Xuefu Zhuyu Decoction in treatment of pain with qi stagnation and blood stasis after transcatheter arterial chemoembolization for primary liver cancer: An analysis of 30 cases[J]. J Anhui Univ Chin Med, 2016, 35(1): 45-47. DOI: 10.3969/j.issn.2095-7246.2016.01.015.
卢冬彦, 叶小卫. 血府逐瘀汤治疗原发性肝癌TACE术后气滞血瘀型疼痛30例[J]. 安徽中医药大学学报, 2016, 35(1): 45-47. DOI: 10.3969/j.issn.2095-7246.2016.01.015.
- [23] MENG TT, ZHANG TT, DENG Q, et al. Effect of Xuefu Zhuyu Decoction assisted XELOX chemotherapy on the expression of serum HIF-1 α and TSP-1 in patients with advanced liver cancer[J]. Chin J Integr Tradit West Med Liver Dis, 2022, 32(7): 606-609. DOI: 10.3969/j.issn.1005-0264.2022.07.009.
孟田田, 张桐桐, 邓秋, 等. 血府逐瘀汤辅助XELOX化疗治疗对晚期肝癌患者血清HIF-1 α 及TSP-1表达的影响[J]. 中西医结合肝病杂志, 2022, 32(7): 606-609. DOI: 10.3969/j.issn.1005-0264.2022.07.009.
- [24] QIAN HL. Clinical observation on treatment of primary liver cancer jaundice with combination of traditional Chinese and western medicine[J]. Mod J Integr Tradit Chin West Med, 2011, 20(24): 3021-3022. DOI: 10.3969/j.issn.1008-8849.2011.24.017.
钱宏利. 中西医结合治疗原发性肝癌黄疸的临床观察[J]. 现代中西医结合杂志, 2011, 20(24): 3021-3022. DOI: 10.3969/j.issn.1008-8849.2011.24.017.
- [25] WU JX, CHEN DZ. Modified Yinchenhao Decoction in treating post-operative jaundice of liver cancer[J]. Zhejiang J Integr Tradit Chin West Med, 2006, 16(3): 160-161. DOI: 10.3969/j.issn.1005-4561.2006.03.018.
吴建新, 陈德忠. 加味茵陈蒿汤治疗肝癌术后黄疸[J]. 浙江中西医结合杂志, 2006, 16(3): 160-161. DOI: 10.3969/j.issn.1005-4561.2006.03.018.
- [26] XU YF. Clinical observation on treating jaundice following primary hepatic carcinoma in the integrative medicine[J]. Clin J Chin Med, 2016, 8(10): 86-87. DOI: 10.3969/j.issn.1674-7860.2016.10.046.
徐跃峰. 中西医结合治疗原发性肝癌黄疸的临床观察[J]. 中医临床研究, 2016, 8(10): 86-87. DOI: 10.3969/j.issn.1674-7860.2016.10.046.
- [27] CHEN YY. Clinical observation on Xiaoyao Powder in treating post-embolization syndrome of liver cancer (liver depression and spleen deficiency syndrome) [D]. Guiyang: Guiyang College of Traditional Chinese Medicine, 2017.
陈岩岩. 逍遥散治疗肝癌介入栓塞后综合征(肝郁脾虚证)临床观察[D]. 贵阳: 贵阳中医学院, 2017.
- [28] CHEN XW, JIANG JW, ZHANG YJ, et al. Clinical observation of Danzhi Xiaoyao Powder for preventing and treating embolism syndrome after transcatheter hepatic arterial chemoembolization in primary liver carcinoma patients differentiated as liver depression and spleen deficiency type[J]. J Guangzhou Univ Tradit Chin Med, 2021, 38(8): 1564-1570. DOI: 10.13359/j.cnki.gzxbtcm.2021.08.005.
陈学武, 姜靖雯, 张永杰, 等. 丹栀逍遥散防治肝郁脾虚型原发性肝癌肝动脉化疗栓塞术后栓塞综合征的临床观察[J]. 广州中医药大学学报, 2021, 38(8): 1564-1570. DOI: 10.13359/j.cnki.gzxbtcm.2021.08.005.
- [29] WANG D. Clinical observation of Danzhi Xiaoyao Powder combined with TACE in the treatment of advanced liver cancer [D]. Xianyang: Shaanxi University of Chinese Medicine, 2021.
王丹. 丹栀逍遥散联合TACE治疗中晚期肝癌的临床疗效观察[D]. 咸阳: 陕西中医药大学, 2021.
- [30] XIONG JL. Clinical observation on 24 cases of primary liver cancer treated by chemotherapy combined with Xiaoyao Powder[J]. Guid J Tradit Chin Med Pharm, 2011, 17(2): 18-20. DOI: 10.13862/j.cnki.cn43-1446/r.2011.02.053.
熊建利. 化疗结合逍遥散加减治疗原发性肝癌24例临床观察[J]. 中医药导报, 2011, 17(2): 18-20. DOI: 10.13862/j.cnki.cn43-1446/r.2011.02.053.
- [31] YANG H. The Clinical Observation on the Effect of Xiaoyaosan Flavored Combined with TACE Treat of Primary Liver Cancer [D]. Nan-ning: Guangxi University of Chinese Medicine, 2018.
杨鹤. 逍遥散加味联合TACE治疗原发性肝癌(肝郁脾虚型)的临床观察[D]. 南宁: 广西中医药大学, 2018.
- [32] LI ZX, XU LJ, WEN XY, et al. Clinical observation of Jiawei Xiaoyao Powder combined with radiofrequency ablation in the treatment of liver cancer[J]. J Med Theory Pract, 2022, 35(5): 794-796. DOI: 10.19381/j.issn.1001-7585.2022.05.027.
李卓娴, 徐丽静, 温小雨, 等. 加味逍遥散联合射频消融术治疗肝癌的疗效观察[J]. 医学理论与实践, 2022, 35(5): 794-796. DOI: 10.19381/j.issn.1001-7585.2022.05.027.
- [33] JI J, HUANG HQ, WANG X, et al. Clinical observation on Xiaoyao Powder combined with intervention of hepatocellular carcinoma of liver-depression and spleen-deficiency syndrome[J]. J Liaoning Univ Tradit Chin Med, 2012, 14(6): 80-82. DOI: 10.13194/j.jluniv-tcm.2012.06.82.jjj.117.
吉婧, 黄慧琴, 王轩, 等. 逍遥散联合介入术对肝郁脾虚型肝癌患者临床疗效观察[J]. 辽宁中医药大学学报, 2012, 14(6): 80-82. DOI: 10.13194/j.jluniv-tcm.2012.06.82.jjj.117.
- [34] XU CX, LI D, NI LQ, et al. Effect of modified Xiaoyao Powder combined with three-dimensional conformal radiotherapy on serum growth factors and immune function in patients with primary liver cancer[J]. J N Chin Med, 2020, 52(4): 26-29. DOI: 10.13457/j.cnki.jncm.2020.04.008.
徐彩霞, 李德, 倪玲琴, 等. 加味逍遥散联合三维适形放疗对原发性肝癌患者血清生长因子及免疫功能的影响[J]. 新中医, 2020, 52(4): 26-29. DOI: 10.13457/j.cnki.jncm.2020.04.008.
- [35] LI X. Clinical observation on modified Yiguan Decoction combined with gamma knife in the treatment of primary liver cancer with yin deficiency of liver and kidney [D]. Changsha: Hunan University of Chinese Medicine, 2020. DOI: 10.27138/d.cnki.ghuzc.2020.000216.
李翔. 一贯煎加味联合伽玛刀治疗肝肾阴虚型原发性肝癌的临床疗效观察[D]. 长沙: 湖南中医药大学, 2020.
- [36] ZHANG LH, ZHUANG ZJ, WANG JC, et al. Clinical study on the treatment of liver cancer with middle and advanced stage by modified Yiguan Jian combined with Argon-helium cryosurgery cryoablation[J]. China J Chin Med, 2015, 30(8): 1092-1094. DOI: 10.16368/j.issn.1674-8999.2015.08.377.
张丽红, 庄志江, 王继成, 等. 加味一贯煎联合氩氦刀冷冻消融术治疗中晚期肝癌临床研究[J]. 中医学报, 2015, 30(8): 1092-1094. DOI: 10.16368/j.issn.1674-8999.2015.08.377.
- [37] LU YQ, LI HB. A clinical observation on supplemented Yiguan brew combined with transcatheter hepatic arterial chemo-embolization for 42 cases of primary liver cancer[J]. J Tradit Chin Med, 2013, 54(5): 405-408. DOI: 10.13288/j.11-2166/r.2013.05.029.
卢义琼, 李华波. 加味一贯煎联合经导管肝动脉栓塞术治疗原发性肝癌42例临床研究[J]. 中医杂志, 2013, 54(5): 405-408. DOI: 10.13288/j.11-2166/r.2013.05.029.
- [38] SUN Y. Effect of Jiawei Yiguan Decoction combined with apatinib mesylate on curative effect and quality of life of patients with advanced primary liver cancer[J]. Yunnan J Tradit Chin Med Mater Med, 2019, 40(4): 56-57. DOI: 10.16254/j.cnki.53-1120/r.2019.04.025.
孙艳. 加味一贯煎联合甲磺酸阿帕替尼对晚期原发性肝癌患者疗效及生存质量的影响[J]. 云南中医中药杂志, 2019, 40(4): 56-57. DOI: 10.16254/j.cnki.53-1120/r.2019.04.025.
- [39] CUI DL, HUANG XB. Effect of Xiangsha Liujunzi Decoction on liver function of patients with primary liver cancer after interventional therapy[J]. Guid J Tradit Chin Med Pharm, 2015, 21(16): 39, 45. DOI: 10.13862/j.cnki.cn43-1446/r.2015.16.012.
崔德利, 黄小兵. 香砂六君子汤对原发性肝癌介入术后患者肝功能的影响[J]. 中医药导报, 2015, 21(16): 39, 45. DOI: 10.13862/j.cnki.cn43-1446/r.2015.16.012.
- [40] ZHANG WW, JIANG YX, YANG D, et al. Systematic review of efficacy and safety of xiaochaihu decoction combined with transcath-

- eter arterial chemoembolization in the treatment of primary liver cancer[J]. Eval Anal Drug Use Hosp China, 2020, 20(2): 149-153, 157. DOI: 10.14009/j.issn.1672-2124.2020.02.005.
- 张雯雯, 蒋吟啸, 杨丹, 等. 小柴胡汤联合经导管动脉栓塞化疗治疗原发性肝癌的有效性与安全性的系统评价[J]. 中国医院用药评价与分析, 2020, 20(2): 149-153, 157. DOI: 10.14009/j.issn.1672-2124.2020.02.005.
- [41] YANG FM, YANG YQ. Xiaochaihu decoction in improvement of side reaction of liver cancer after radiofrequency ablation for 32 cases [J]. Chin Med Mod Distance Educ China, 2015, 13(20): 50-52. DOI: 10.3969/j.issn.1672-2779.2015.20.026.
- 杨芳明, 杨亚琴. 小柴胡汤改善肝癌射频消融术后不良反应32例[J]. 中国中医药现代远程教育, 2015, 13(20): 50-52. DOI: 10.3969/j.issn.1672-2779.2015.20.026.
- [42] WANG WY, ZHANG KQ, LIU JM, et al. Clinical study of Jiawei xiaochaihutang combined with microwave ablation in treatment of primary hepatocellular carcinoma[J]. Chin J Exp Tradit Med Formulae, 2022, 28(7): 121-126. DOI: 10.13422/j.cnki.syfjx.20220794.
- 王文英, 张克勤, 刘金明, 等. 加味小柴胡汤联合微波消融治疗原发性肝癌的临床疗效[J]. 中国实验方剂学杂志, 2022, 28(7): 121-126. DOI: 10.13422/j.cnki.syfjx.20220794.
- [43] ZHAO WW, SUN HT, CHEN ZM, et al. Clinical observation of Xiaochaihu Decoction combined with microwave ablation and portal vein perfusion in the treatment of primary liver cancer[J]. Chin J Integr Tradit West Med Dig, 2017, 25(7): 543-546. DOI: 10.3969/j.issn.1671-038X.2017.07.17.
- 赵威武, 孙厚坦, 陈朝昊, 等. 小柴胡汤联合微波消融并门静脉灌注治疗原发性肝癌的临床观察[J]. 中国中西医结合消化杂志, 2017, 25(7): 543-546. DOI: 10.3969/j.issn.1671-038X.2017.07.17.
- [44] LI ZJ, LIANG D, ZHANG YC, et al. Clinical study on Xiaochaihu Decoction combined with Liuwei Dihuang Decoction to prevent and treat 50 cases of post-embolism syndrome after TACE for primary liver cancer[J]. Jiangsu J Tradit Chin Med, 2020, 52(5): 38-41. DOI: 10.19844/j.cnki.1672-397X.2020.05.010.
- 李正军, 梁定, 张元朝, 等. 小柴胡汤合六味地黄汤加减防治原发性肝癌TACE术后栓塞后综合征50例临床研究[J]. 江苏中医药, 2020, 52(5): 38-41. DOI: 10.19844/j.cnki.1672-397X.2020.05.010.
- [45] YANG CJ. Clinical Observation of Jiawei Xiaochaihu Decoction combined with sorafenib in the treatment of middle and advanced primary liver cancer[D]. Chengdu: Chengdu University of Traditional Chinese Medicine, 2021.
- 杨彩杰. 加味小柴胡汤联合索拉非尼治疗中晚期原发性肝癌的临床观察[D]. 成都: 成都中医药大学, 2021.
- [46] CHEN XW, JIANG JW, LIN FH. Longdan Xiegan Decoction in the treatment of embolism syndrome after interventional therapy on primary hepatocellular carcinoma[J]. J Nanjing Univ Tradit Chin Med, 2016, 32(3): 224-228. DOI: 10.14148/j.issn.1672-0482.2016.0224.
- 陈学武, 姜靖雯, 林福煌. 龙胆泻肝汤治疗原发性肝癌TACE术后栓塞综合征的疗效观察[J]. 南京中医药大学学报, 2016, 32(3): 224-228. DOI: 10.14148/j.issn.1672-0482.2016.0224.
- [47] ZHANG CJ. Observation on therapeutic effect of Longdan Xiegan Decoction on embolism syndrome after TACE for primary liver cancer[J]. Mod J Integr Tradit Chin West Med, 2017, 26(27): 3001-3003. DOI: 10.3969/j.issn.1008-8849.2017.27.012.
- 张承军. 龙胆泻肝汤治疗原发性肝癌TACE术后栓塞综合征疗效观察[J]. 现代中西医结合杂志, 2017, 26(27): 3001-3003. DOI: 10.3969/j.issn.1008-8849.2017.27.012.
- [48] FAN WX, WANG SH, HUANG R, et al. Clinical observation on the treatment of 41 cases of gastrointestinal dysfunction after interventional chemotherapy and embolization of primary liver cancer with Simotang oral liquid[J]. Chin J Integr Tradit West Med Dig, 2016, 24(8): 632-633. DOI: 10.3969/j.issn.1671-038X.2016.08.17.
- 范文轩, 王三虎, 黄瑞, 等. 四磨汤口服液治疗原发性肝癌介入化疗栓塞术后胃肠功能障碍41例临床观察[J]. 中国中西医结合消化杂志, 2016, 24(8): 632-633. DOI: 10.3969/j.issn.1671-038X.2016.08.17.
- [49] YI CH. Clinical observation of Simo decoction combined with lactulose in treatment of constipation after interventional therapy of liver cancer[J]. J Hubei Univ Chin Med, 2015, 17(3): 59-60. DOI: 10.3969/j.issn.1008-987x.2015.03.19.
- 易长虹. 四磨汤联合乳果糖口服液治疗肝癌介入术后便秘疗效观察[J]. 湖北中医药大学学报, 2015, 17(3): 59-60. DOI: 10.3969/j.issn.1008-987x.2015.03.19.
- [50] XUE WH. Integrated diagnosis and treatment plan of traditional Chinese and Western medicine for primary liver cancer[C]//Proceedings of the 2013 Academic Symposium on New Advances in Multi-disciplinary Comprehensive Diagnosis and Treatment of Cancer. Hangzhou, 2013: 148.
- 薛文瀚. 原发性肝癌中西医结合诊疗方案[C]//2013年肿瘤多学科综合诊治新进展学术研讨会论文集. 杭州, 2013: 148.
- [51] CHEN Q, CHEN XP. Adjuvant Huaier Granule for hepatocellular carcinoma after curative resection: A phase IV, multicenter, randomized, and parallel-group controlled clinical trial[J]. J Hepatol, 2017, 66(1): S622. DOI: 10.1016/s0168-8278(17)31689-6.
- [52] ZHANG QH, LIANG YH. Clinical efficacy of Huaier Granule combined with sorafenib on patients with postoperative recurrence of primary liver cancer[J]. Pract J Cancer, 2019, 34(9): 1560-1562. DOI: 10.3969/j.issn.1001-5930.2019.09.049.
- 张庆辉, 梁艳华. 槐耳颗粒联合索拉非尼对原发性肝癌术后复发患者的临床疗效研究[J]. 实用癌症杂志, 2019, 34(9): 1560-1562. DOI: 10.3969/j.issn.1001-5930.2019.09.049.
- [53] HAN DZ. Effects of Huaier Granules combined with sorafenib on postoperative recurrence patients with primary hepatocellular carcinoma and its effects on alpha-fetoprotein-L3 level[J]. China J Pharm Econ, 2022, 17(1): 64-67. DOI: 10.12010/j.issn.1673-5846.2022.01.013.
- 韩大志. 槐耳颗粒与索拉非尼联用对原发性肝癌术后复发患者的作用效果及对甲胎蛋白、甲胎蛋白异质体-L3水平的影响[J]. 中国药物经济学, 2022, 17(1): 64-67. DOI: 10.12010/j.issn.1673-5846.2022.01.013.
- [54] LI H, ZHANG B, YU GY. Preventive effect of Jinlong capsule on recurrence and metastasis of resectable liver cancer after operation [J]. Cap Med, 2007, 14(24): 35-36.
- 李辉, 张波, 于国泳. 金龙胶囊对可切除肝癌手术后复发和转移的预防作用[J]. 首都医药, 2007, 14(24): 35-36.
- [55] XIE B, TANG C, HUANG J. Effect of jinlong capsule combined with hepatectomy on HCC intrahepatic metastasis[J]. Chin J Cancer Prev Treat, 2008, 15(20): 1584-1586. DOI: 10.16073/j.cnki.cjcp.2008.20.017.
- 谢斌, 唐春, 黄建. 金龙胶囊对肝癌切除后复发转移影响的初步临床观察[J]. 中华肿瘤防治杂志, 2008, 15(20): 1584-1586. DOI: 10.16073/j.cnki.cjcp.2008.20.017.
- [56] WANG C, BAI H, XIAO H, et al. Effect of cinobufotalin capsule combined with interferon- α on postoperative immune function and long-term prognosis in patients with small hepatocellular carcinoma[J]. World Clin Drugs, 2022, 43(5): 554-558, 564. DOI: 10.13683/j.wph.2022.05.011.
- 王琛, 白桦, 肖慧, 等. 华蟾素胶囊联合 α 干扰素对原发性小肝癌患者术后免疫功能和远期预后的影响[J]. 世界临床药物, 2022, 43(5): 554-558, 564. DOI: 10.13683/j.wph.2022.05.011.
- [57] ZHANG DW, HE J, ZHANG HG, et al. Study on the effect of compound Sophora flavescens injection combined with intraoperative margin treatment on postoperative recurrence and metastasis of patients with primary liver cancer[J]. Mod J Integr Tradit Chin West Med, 2017, 26(21): 2348-2350. DOI: 10.3969/j.issn.1008-8849.2017.21.024.
- 张大为, 何津, 张海光, 等. 复方苦参注射液配合术中切缘处理对原发性肝癌患者术后复发转移的影响研究[J]. 现代中西医结合杂志, 2017, 26(21): 2348-2350. DOI: 10.3969/j.issn.1008-8849.2017.21.024.
- [58] CHENG L, ZHU AX. Effect of Shenqi Fuzheng injection on immune

- function of patients after laparoscopic radical resection of liver cancer[J]. *Int Med Health Guid Issues*, 2015, 21(21): 3209-3211. DOI: 10.3760/cma.j.issn.1007-1245.2015.21.036.
- 程亮, 朱爱欣. 参芪扶正注射液对腹腔镜肝癌根治术后患者免疫功能的影响[J]. *国际医药卫生导报*, 2015, 21(21): 3209-3211. DOI: 10.3760/cma.j.issn.1007-1245.2015.21.036.
- [59] LI CC. Effect of Shenqifuzhen injection on immunity of postoperative patients of hepatocellular carcinoma[D]. Nanjing: Nanjing University of Chinese Medicine.
李晨晨. 参芪扶正注射液对肝癌术后患者免疫功能的影响[D]. 南京: 南京中医药大学.
- [60] CHEN R, ZHOU YT, WANG JC. Observation of curative effect of Shengmai injection in adjuvant treatment of hepatocellular carcinoma[J]. *J N Chin Med*, 2015, 47(7): 121-122. DOI: 10.13457/j.cnki.jncm.2015.07.054.
陈荣, 周榆腾, 王建春. 生脉注射液辅助治疗肝癌术后疗效观察[J]. *新中医*, 2015, 47(7): 121-122. DOI: 10.13457/j.cnki.jncm.2015.07.054.
- [61] YAN KQ, WANG JY, LI G, et al. Meta-analysis of randomized controlled trials of jinlong capsules combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer[J]. *J Oncol Chin Med*, 2021, 3(2): 95-102. DOI: 10.19811/j.cnki.ISSN2096-6628.2021.02.021.
颜克秋, 王剑一, 李格, 等. 金龙胶囊联合经导管肝动脉化疗栓塞术治疗原发性肝癌的疗效和安全性的Meta分析[J]. *中医肿瘤学杂志*, 2021, 3(2): 95-102. DOI: 10.19811/j.cnki.ISSN2096-6628.2021.02.021.
- [62] XU XH, WU Y, YI KJ, et al. Overview on systematic reviews of huachansu injection combined with transcatheter arterial chemoembolization for treatment of liver cancer[J]. *Chin J Inf Tradit Chin Med*, 2022, 29(4): 27-33. DOI: 10.19879/j.cnki.1005-5304.202105334.
徐晓华, 吴煜, 移康军, 等. 华蟾素注射液联合肝动脉化疗栓塞治疗肝癌的系统评价再评价[J]. *中国中医药信息杂志*, 2022, 29(4): 27-33. DOI: 10.19879/j.cnki.1005-5304.202105334.
- [63] YANG ZM, LIU M, LIN SM, et al. Meta-analysis of the efficacy and safety of transhepatic arterial perfusion of elemenum emulsion combined with transcatheter arterial chemoembolization in the treatment of primary hepatic carcinoma[J]. *J Guangzhou Univ Tradit Chin Med*, 2022, 39(11): 2701-2708. DOI: 10.13359/j.cnki.gzxbtcm.2022.11.039.
杨子媚, 刘蒙, 林尚明, 等. 经肝动脉灌注榄香烯乳剂联合经肝动脉化疗栓塞术治疗原发性肝癌疗效及安全性的Meta分析[J]. *广州中医药大学学报*, 2022, 39(11): 2701-2708. DOI: 10.13359/j.cnki.gzxbtcm.2022.11.039.
- [64] YANG WL, XU HM, ZHAO HL, et al. Meta-analysis of clinical efficacy and safety of compound Kushen injection combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer[J]. *Lishizhen Med Mater Med Res*, 2022, 33(3): 767-770. DOI: 10.3969/j.issn.1008-0805.2022.03.75.
阳卫立, 徐豪明, 赵海兰, 等. 复方苦参注射液联合肝动脉化疗栓塞术治疗原发性肝癌临床疗效及安全性的Meta分析[J]. *时珍国医国药*, 2022, 33(3): 767-770. DOI: 10.3969/j.issn.1008-0805.2022.03.75.
- [65] CHEN JJ, YU ZP, YAO Y, et al. Huisheng oral liquid combined with TACE for treatment of primary hepatic carcinoma: Meta-analysis[J]. *Chin J Interv Imag Ther*, 2019, 16(9): 545-549. DOI: 10.13929/j.1672-8475.201903023.
陈建建, 尉泽鹏, 姚远, 等. Meta分析回生口服液联合TACE治疗原发性肝癌疗效[J]. *中国介入影像与治疗学*, 2019, 16(9): 545-549. DOI: 10.13929/j.1672-8475.201903023.
- [66] LIN RT, CHEN ZQ, LIN JT, et al. Efficacy and safety of xiaoaijing injection combined with transcatheter arterial chemoembolization in treatment of primary hepatic carcinoma: A meta-analysis[J]. *World J Integr Tradit West Med*, 2020, 15(10): 1783-1789. DOI: 10.13935/j.cnki.sjzx.201005.
林瑞婷, 陈芝强, 林洁涛, 等. 消癌平注射液联合TACE治疗原发性肝癌临床疗效与安全性的Meta分析[J]. *世界中西医结合杂志*, 2020, 15(10): 1783-1789. DOI: 10.13935/j.cnki.sjzx.201005.
- [67] ZHENG JW, ZHANG D, WU JR, et al. Meta-analysis on the randomized controlled trials of aidi injection treating for liver carcinoma[J]. *Chin J Pharmacoepidemiol*, 2017, 26(8): 540-546. DOI: 10.19960/j.cnki.issn1005-0698.2017.08.006.
郑捷文, 张丹, 吴嘉瑞, 等. 艾迪注射液辅助治疗肝癌的Meta分析[J]. *药物流行病学杂志*, 2017, 26(8): 540-546. DOI: 10.19960/j.cnki.issn1005-0698.2017.08.006.
- [68] LIU YS, BAI Y, LV SQ, et al. A meta-analysis on the efficacy and safety of Brucea javanica oil emulsion combined with TACE in treating moderate or advanced primary liver cancer[J]. *Chin J Integr Tradit West Med*, 2017, 37(9): 1063-1068. DOI: 10.7661/j.cjtm.20170622.162.
刘应生, 白钰, 吕书勤, 等. 鸦胆子油乳联合TACE治疗中晚期原发性肝癌疗效和安全性Meta分析[J]. *中国中西医结合杂志*, 2017, 37(9): 1063-1068. DOI: 10.7661/j.cjtm.20170622.162.
- [69] MA X, HE X, LI HT, et al. Meta-analysis of Kang'ai Injection combined with TACE in treating primary hepatic carcinoma[J]. *Chin Tradit Pat Med*, 2019, 41(7): 1564-1572. DOI: 10.3969/j.issn.1001-1528.2019.07.016.
马骁, 何璇, 李浩田, 等. 康艾注射液联合TACE治疗原发性肝癌的Meta分析[J]. *中成药*, 2019, 41(7): 1564-1572. DOI: 10.3969/j.issn.1001-1528.2019.07.016.
- [70] YANG WT, HOU EC. Efficacy and safety of Shenqi Fuzheng Injection combined with transcatheter arterial chemoembolization for primary liver cancer: A Meta analysis[J]. *China Med Her*, 2017, 14(19): 110-113.
杨婉婷, 侯恩存. 参芪扶正注射液联合经肝动脉化疗栓塞术治疗原发性肝癌效果与安全性的Meta分析[J]. *中国医药导报*, 2017, 14(19): 110-113.
- [71] ZHANG SH, TANG Y, YUE H, et al. Efficacy of Huaier Granule combined with transcatheter arterial chemoembolization in treatment of primary liver cancer: A meta analysis[J]. *Chin J Bases Clin Gen Surg*, 2020, 27(7): 855-860. DOI: 10.7507/1007-9424.201910035.
张少华, 唐盈, 岳瀚, 等. 槐耳颗粒联合经导管肝动脉化疗栓塞治疗原发性肝癌疗效的meta分析[J]. *中国普外基础与临床杂志*, 2020, 27(7): 855-860. DOI: 10.7507/1007-9424.201910035.
- [72] SUN L, REN JX, TIAN Y, et al. A randomized, double-blind and multi-centre study of interventional chemotherapy combined with yangzhengxiaoji capsule in treating primary hepatic carcinoma[J]. *World Chin Med*, 2013, 8(6): 688-691. DOI: 10.3969/j.issn.1673-7202.2013.06.034.
孙利, 任君霞, 田野, 等. 养正消积胶囊配合介入化疗治疗原发性肝癌随机双盲多中心临床研究[J]. *世界中医药*, 2013, 8(6): 688-691. DOI: 10.3969/j.issn.1673-7202.2013.06.034.
- [73] ZHANG SY, GU CH, GAO XD, et al. Randomized double-blind multi-center clinical study of Yangzhengxiaoji capsule assisted interventional chemotherapy for primary liver cancer[C]. Beijing, Chinese: 10th International Congress of Collaterals, 2014.
张水艳, 谷春华, 高学东, 等. 养正消积胶囊辅助介入化疗治疗原发性肝癌的随机双盲多中心临床研究[C]. 北京, 中国: 第十届国际络病学大会, 2014.
- [74] CHENG CY, CAI SY, FENG L. Clinical study of yangzheng xiaoji capsule assisted interventional chemotherapy in the treatment of patients with primary liver cancer[J]. *Chin J Pract Med*, 2020, 47(18): 114-117. DOI: 10.3760/cma.j.cn115689-20200606-02861.
程崇勇, 蔡尚原, 冯磊. 养正消积胶囊辅助介入化疗治疗原发性肝癌的临床研究[J]. *中国实用医刊*, 2020, 47(18): 114-117. DOI: 10.3760/cma.j.cn115689-20200606-02861.
- [75] SONG DG, TAN P, SHI H. Efficacy observation of yangzhengxiaoji capsule combined with hepatic artery chemotherapy embolism in improving liver function in patients with primary hepatic carcinoma[J]. *World Chin Med*, 2013, 8(8): 973-975. DOI: 10.3969/j.issn.1673-7202.2013.08.042.

- 宋旦哥, 谭萍, 史华. 养正消积胶囊联合肝动脉化疗栓塞治疗对原发性肝癌患者肝功能改善的疗效观察[J]. 世界中医药, 2013, 8(8): 973-975. DOI: 10.3969/j.issn.1673-7202.2013.08.042.
- [76] SHU JH, ZHOU RY, WANG WH. Clinical observation of "Yangzheng Xiaoji Capsule" and interventional chemotherapy in treating primary liver cancer[J]. Shanghai J Tradit Chin Med, 2013, 47(6): 30-31. DOI: 10.16305/j.1007-1334.2013.06.043.
- 束家和, 周荣耀, 王文海. 养正消积胶囊结合化疗治疗原发性肝癌临床观察[J]. 上海中医药杂志, 2013, 47(6): 30-31. DOI: 10.16305/j.1007-1334.2013.06.043.
- [77] YAN YZ, TANG H, YOU J. Meta-analysis of efficacy of Ganfule combined with TACE in the treatment of hepatocellular carcinoma[J]. China Med Her, 2020, 17(32): 87-91.
- 晏远智, 唐恒, 游晶. 肝复乐联合肝动脉化疗栓塞术治疗肝细胞癌有效性的meta分析[J]. 中国医药导报, 2020, 17(32): 87-91.
- [78] SUN DX, YANG Z, LONG FX, et al. Efficacy and safety of Kanglaite injection combined with transarterial chemoembolization in treatment of advanced liver cancer: A Meta-analysis[J]. J Clin Hepatol, 2020, 36(2): 363-368. DOI: 10.3969/j.issn.1001-5256.2020.02.026.
- 孙冬雪, 杨柱, 龙奉玺, 等. 康莱特注射液联合经肝动脉化疗栓塞术治疗中晚期肝癌效果的Meta分析[J]. 临床肝胆病杂志, 2020, 36(2): 363-368. DOI: 10.3969/j.issn.1001-5256.2020.02.026.
- [79] LIU GF, LI F, BI XJ, et al. Systematic review of clinical effects of Cidan capsules combined with TACE in treatment against primary liver cancer[J]. Chin J Hosp Pharm, 2016, 36(17): 1496-1500. DOI: 10.13286/j.cnki.chinhosp-pharmacy.2016.17.15.
- 刘光甫, 黎飞, 毕雪洁, 等. 慈丹胶囊联合TACE治疗原发性肝癌临床效果的系统评价[J]. 中国医院药学杂志, 2016, 36(17): 1496-1500. DOI: 10.13286/j.cnki.chinhosp-pharmacy.2016.17.15.
- [80] YE X, GE ZM, FEI XB, et al. Clinical study on HIFU combined with jinlong capsules in treating 54 cases of primary liver cancer[J]. Chin J Clin Oncol, 2008, 35(7): 372-374. DOI: 10.3969/j.issn.1000-8179.2008.07.004.
- 叶欣, 葛忠民, 费兴波, 等. 高强度聚焦超声联合金龙胶囊治疗原发性肝癌54例疗效分析[J]. 中国肿瘤临床, 2008, 35(7): 372-374. DOI: 10.3969/j.issn.1000-8179.2008.07.004.
- [81] FANG XH, XU J. Cantharidin sodium vitamin B6 injection as assistant therapy for treating liver cancer in 37 cases[J]. China Pharm, 2016, 25(1): 25-26, 27.
- 方秀华, 徐洁. 斑蝥酸钠维生素B6注射液辅助治疗肝癌37例疗效评价[J]. 中国药业, 2016, 25(1): 25-26, 27.
- [82] YANG WL. Clinical efficacy of compound Kushen injection against liver cancer and the proliferation and autophagy of liver cancer cells in vitro[D]. Guangzhou: Guangzhou Medical University, 2021.
- 阳卫立. 复方苦参注射液治疗肝癌的临床疗效分析及体外对肝癌细胞增殖和自噬的影响[D]. 广州: 广州医科大学, 2021.
- [83] CHU JS, WU QY, HUANG YQ, et al. Effect of Yangzhengxiaoji capsule combined with thalidomide on quality of life after TACE for advanced hepatocellular carcinoma[J]. Asia Pac Tradit Med, 2016, 12(24): 159-161. DOI: 10.11954/j.issn.1672-4992.2016.24.070.
- 楚建设, 吴清芝, 黄印强, 等. 养正消积胶囊联合沙利度胺对中晚期肝癌TACE术后生存质量影响研究[J]. 亚太传统医药, 2016, 12(24): 159-161. DOI: 10.11954/j.issn.1672-4992.2016.24.070.
- [84] HUANG WK, YOU LN. Clinical observation of Yangzheng Xiaoji Capsule in reducing adverse reactions after TACE in patients with advanced primary liver cancer[C]. Guangzhou, Chinese: 13th International Congress of Collaterals, 2017.
- 黄伍奎, 由丽娜. 养正消积胶囊减少晚期原发性肝癌患者TACE术后不良反应的临床观察[C]. 广州, 中国: 第十三届国际络病学大会, 2017.
- [85] LI H, LI HX, WANG XX. Efficacy of Xuebijing injection in the treatment of post-interventional Syndrome of primary liver cancer and its effects on liver function and serum CRP, TNF-AND VEGF levels[J/CD]. Chin J Interv Radiol Electron Ed, 2022, 10(1): 27-31. DOI: 10.3877/cma.j.issn.2095-5782.2022.01.005.
- 李辉, 李海霞, 王秀香. 血必净注射液辅助治疗原发性肝癌介入术后综合征的临床研究[J/CD]. 中华介入放射学电子杂志, 2022, 10(1): 27-31. DOI: 10.3877/cma.j.issn.2095-5782.2022.01.005.
- [86] WEI SF. Clinical Observation of Xuebijing Injection in Reducing Primary Liver Cancer Post-chemoembolization Syndrome[D]. Guangzhou: Guangzhou University of Chinese Medicine, 2018.
- 魏素芬. 血必净注射液减轻原发性肝癌化疗栓塞后综合征的临床观察[D]. 广州: 广州中医药大学, 2018.
- [87] XIANG DK, XIE JY, WANG D, et al. Study on Xuebijing injection on plasma endotoxin and VEGF of the liver cancer treated with transcatheter arterial chemoembolization[J]. China J Mod Med, 2013, 23(35): 88-92.
- 向大开, 谢家印, 王东, 等. 血必净对肝癌经导管肝动脉化疗栓塞术后血浆内毒素、VEGF影响的临床研究[J]. 中国现代医学杂志, 2013, 23(35): 88-92.
- [88] MAO YQ, WU XX, DENG J, et al. Influence of Xuebijing injection on plasma endotoxin and liver function of the liver cancer treated with transcatheter arterial chemoembolization[J]. Chin J Integr Tradit West Med Dig, 2011, 19(4): 224-226.
- 毛燕群, 吴晓霞, 邓俊, 等. 血必净对肝癌经导管肝动脉化疗栓塞术后血浆内毒素及肝功能的影响[J]. 中国中西医结合消化杂志, 2011, 19(4): 224-226.
- [89] LUO HY, WU WY, LU JR, et al. Effects of Qingkailing in jection on post-transcatheter arterial chemoembolization syndrome in patients with primary liver cancer[J]. J Guangzhou Univ Tradit Chin Med, 2001, 18(2): 130-133. DOI: 10.3969/j.issn.1007-3213.2001.02.011.
- 罗海英, 吴万垠, 卢君仁, 等. 清开灵注射液治疗原发性肝癌介入后综合征[J]. 广州中医药大学学报, 2001, 18(2): 130-133. DOI: 10.3969/j.issn.1007-3213.2001.02.011.
- [90] ZHANG Y. Clinical efficacy of entecavir combined with Kangai injection in the treatment of HBV-related hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. Mod J Integr Tradit Chin West Med, 2015, 24(30): 3363-3365. DOI: 10.3969/j.issn.1008-8849.2015.30.021.
- 张颖. 恩替卡韦联合康艾注射液对HBV相关性肝癌肝动脉栓塞化疗后的临床疗效[J]. 现代中西医结合杂志, 2015, 24(30): 3363-3365. DOI: 10.3969/j.issn.1008-8849.2015.30.021.
- [91] KANG SL, RAO ZG, YANG B. Observation of Kang' Ai- injection on quality of life in patients with hepatocellular carcinoma after TACE[J]. J Mod Oncol, 2015, 23(1): 92-94. DOI: 10.3969/j.issn.1672-4992.2015.01.26.
- 康朔麟, 饶智国, 杨波. 康艾注射液对肝癌患者TACE术后生活质量的影响[J]. 现代肿瘤医学, 2015, 23(1): 92-94. DOI: 10.3969/j.issn.1672-4992.2015.01.26.
- [92] WANG LAA, PENG LS, WEI CS. Clinical observation on 30 cases of hepatitis B-related primary hepatocellular carcinoma after transcatheter arterial chemoembolization treated by compound Yexiazhu Granule combined with western medicine[J]. J Tradit Chin Med, 2017, 58(22): 1939-1942. DOI: 10.13288/j.11-2166/r.2017.22.011.
- 王李安, 彭立生, 魏春山. 复方叶下珠颗粒剂联合西药治疗乙型肝炎相关原发性肝癌经肝动脉化疗栓塞术后患者30例临床观察[J]. 中医杂志, 2017, 58(22): 1939-1942. DOI: 10.13288/j.11-2166/r.2017.22.011.
- [93] ZHANG LM, LI XX, TANG RF, et al. Study on babaodan capsule in prevention and treatment of post-chemoembolization syndrome of hepatocellular carcinoma[J]. J Hebei Tradit Chin Med Pharmacol, 2018, 33(1): 26-28. DOI: 10.16370/j.cnki.13-1214/r.2018.01.008.
- 张丽敏, 李新省, 唐瑞峰, 等. 八宝丹胶囊防治肝癌化疗栓塞术后综合征的研究[J]. 河北中医药学报, 2018, 33(1): 26-28. DOI: 10.16370/j.cnki.13-1214/r.2018.01.008.
- [94] XU Y, LI W, LOU MZ, et al. Clinical study on babaodan capsules for postoperative syndrome in patients undergoing chemoembolization for primary hepatocellular carcinoma[J]. J N Chin Med, 2020, 52(16): 104-106. DOI: 10.13457/j.cnki.jncm.2020.16.029.
- 徐意, 李伟, 楼妙姿, 等. 八宝丹胶囊治疗原发性肝癌化疗栓塞术后综合

- 征临床研究[J]. 新中医, 2020, 52(16): 104-106. DOI: 10.13457/j.cnki.jncm.2020.16.029.
- [95] LIU LN, QIU XD, ZHANG GJ, et al. Effect of Xihuang capsule on liver function and cellular immune function after TACE for hepatocellular carcinoma[J]. Yunnan J Tradit Chin Med Mater Med, 2022, 43(7): 46-49. DOI: 10.16254/j.cnki.53-1120/r.2022.07.014.
- 刘利娜, 裴兴栋, 章国晶, 等. 西黄胶囊对肝癌TACE术后肝功能及细胞免疫功能的影响[J]. 云南中医中药杂志, 2022, 43(7): 46-49. DOI: 10.16254/j.cnki.53-1120/r.2022.07.014.
- [96] MI CF, YU SY. Clinical analysis of Huaier Granule combined with CT-guided Iodine-125 (¹²⁵I) particles implantation for advanced hepatocellular carcinoma[J]. Chin J Pract Med, 2016, 43(12): 75-77. DOI: 10.3760/cma.j.issn.1674-4756.2016.12.031.
- 米彩锋, 余守雅. 槐耳颗粒联合¹²⁵I放射性粒子植入术治疗中晚期肝癌的疗效分析[J]. 中国实用医刊, 2016, 43(12): 75-77. DOI: 10.3760/cma.j.issn.1674-4756.2016.12.031.
- [97] XIAO ZY, DENG JH, XIONG SZ, et al. Three-dimensional conformal radiotherapy combined with Jinlong capsule in the treatment of 52 cases of primary liver cancer[J]. Cap Med, 2009, 16(16): 45-46.
- 肖震宇, 邓江华, 熊士忠, 等. 三维适形放疗联合金龙胶囊治疗原发性肝癌52例疗效分析[J]. 首都医药, 2009, 16(16): 45-46.
- [98] DU ZQ, JIANG LJ, ZHANG ZC, et al. Efficacy of argon-helium cryoablation combined with cinobufotalin and Shenmai injection in the treatment of advanced primary liver cancer[J]. Guangdong Med J, 2008, 29(10): 1666-1667. DOI: 10.13820/j.cnki.gdyx.2008.10.065.
- 杜志强, 姜良进, 张宗成, 等. 氩氦刀消融联合华蟾素和生脉注射液治疗肝癌的疗效观察[J]. 广东医学, 2008, 29(10): 1666-1667. DOI: 10.13820/j.cnki.gdyx.2008.10.065.
- [99] ZHANG XY, HU YH, TANG CG, et al. Clinical research of stereotactic conformal body γ -knife and cinobufacini on patients with hepatocellular carcinoma[J/CD]. Chin J Clin Electron Ed, 2011, 5(7): 1901-1905. DOI: 10.3877/cma.j.issn.1674-0785.2011.07.007.
- 张小玉, 呼永河, 唐春果, 等. 华蟾素辅助立体定向体部伽玛刀治疗原发性肝癌的临床研究[J/CD]. 中华临床医师杂志(电子版), 2011, 5(7): 1901-1905. DOI: 10.3877/cma.j.issn.1674-0785.2011.07.007.
- [100] JIAO QS, ZENG BZ. Combination of cinobufotalin tablets and radioactive ¹²⁵I particle implantation on peripheral blood T lymphocyte subsets after operation and serum CEA and AFP levels change in patients with advanced primary liver cancer[J]. J Mod Oncol, 2018, 26(10): 1565-1569. DOI: 10.3969/j.issn.1672-4992.2018.10.022.
- 焦勤书, 曾宝珠. 华蟾素片联合¹²⁵I粒子植入术治疗晚期原发性肝癌疗效及对相关血液生化指标的影响[J]. 现代肿瘤医学, 2018, 26(10): 1565-1569. DOI: 10.3969/j.issn.1672-4992.2018.10.022.
- [101] KUANG YH, XU FB, ZHAO Z, et al. Meta-analysis and trial sequential analysis of effectiveness and safety of compound Banmao capsules combined with different chemoradiotherapy in the treatment of primary hepatic carcinoma[J]. China Pharm, 2021, 32(8): 996-1003. DOI: 10.6039/j.issn.1001-0408.2021.08.17.
- 邝玉慧, 徐方飏, 赵哲, 等. 复方斑蝥胶囊联合不同放化疗方案治疗原发性肝癌有效性与安全性的Meta分析及试验序贯分析[J]. 中国药房, 2021, 32(8): 996-1003. DOI: 10.6039/j.issn.1001-0408.2021.08.17.
- [102] ZHANG CZ, WANG JS. Clinical observation of primary liver cancer treated with aidi injection combined with little dose chemotherapy[J]. J Basic Clin Oncol, 2007, 20(2): 143-144. DOI: 10.3969/j.issn.1673-5412.2007.02.021.
- 张春珍, 王俊生. 艾迪注射液联合小剂量化疗治疗肝癌的疗效观察[J]. 肿瘤基础与临床, 2007, 20(2): 143-144. DOI: 10.3969/j.issn.1673-5412.2007.02.021.
- [103] YANG SR, WANG R, CHAI LX, et al. Clinical observation of Aidi injection combined with three-dimensional conformal radiotherapy for advanced primary liver cancer[J]. Shaanxi J Tradit Chin Med, 2017, 38(11): 1495-1496. DOI: 10.3969/j.issn.1000-7369.2017.11.003.
- 杨世荣, 王嵘, 柴丽霞, 等. 艾迪注射液联合三维适形放疗治疗中晚期原发性肝癌临床观察[J]. 陕西中医, 2017, 38(11): 1495-1496. DOI: 10.3969/j.issn.1000-7369.2017.11.003.
- [104] ZHANG DW, HE J, WU HJ, et al. Clinical effects of FP and Addie injection combined with ¹²⁵I seed implantation in treating advanced primary liver cancer[J]. Hainan Med J, 2016, 27(23): 3844-3847. DOI: 10.3969/j.issn.1003-6350.2016.23.019.
- 张大为, 何津, 吴会静, 等. FP+艾迪注射液联合¹²⁵I粒子植入治疗中晚期原发性肝癌的临床研究[J]. 海南医学, 2016, 27(23): 3844-3847. DOI: 10.3969/j.issn.1003-6350.2016.23.019.
- [105] ZHANG BW, FENG SX, LI ZX, et al. Clinical analysis of compound Kushen injection combined with gamma knife in the treatment of primary liver cancer[J]. Nei Mongol J Tradit Chin Med, 2011, 30(22): 9-10, 37. DOI: 10.16040/j.cnki.cn15-1101.2011.22.193.
- 章炳蔚, 冯守信, 李忠喜, 等. 复方苦参注射液联合体部伽玛刀治疗原发性肝癌临床疗效分析[J]. 内蒙古中医药, 2011, 30(22): 9-10, 37. DOI: 10.16040/j.cnki.cn15-1101.2011.22.193.
- [106] JIANG X, GAO GY, WANG W, et al. Clinical study of compound Kushen injection combined with radioactive ¹²⁵I seed implantation in the treatment of primary liver cancer[J]. Guizhou Med J, 2017, 41(1): 39-41. DOI: 10.3969/j.issn.1000-744X.2017.01.015.
- 蒋璇, 高广毅, 王伟, 等. 复方苦参注射液联合放射性¹²⁵I粒子植入治疗原发性肝癌的临床研究[J]. 贵州医药, 2017, 41(1): 39-41. DOI: 10.3969/j.issn.1000-744X.2017.01.015.
- [107] ZHU YL, YI FT. The effect of γ knife the combined application of Danshen injections on immune function in patients with primary liver cancer[J]. Chin J Integr Tradit West Med Liver Dis, 2020, 30(2): 111-113. DOI: 10.3969/j.issn.1005-0264.2020.02.005.
- 朱亚玲, 易峰涛. 复方丹参注射液联合伽玛刀治疗对原发性肝癌患者免疫功能的影响[J]. 中西医结合肝病杂志, 2020, 30(2): 111-113. DOI: 10.3969/j.issn.1005-0264.2020.02.005.
- [108] SHAO L, SHI YX, ZHU HX, et al. Clinical study of stereotactic radiotherapy combined with Kanglaite injection in the treatment of primary liver cancer[J]. Clin J Med Off, 2017, 45(3): 313-315. DOI: 10.16680/j.1671-3826.2017.03.28.
- 邵亮, 施艳新, 朱慧心, 等. 立体定向放射治疗联合康莱特注射液治疗原发性肝癌临床研究[J]. 临床军医杂志, 2017, 45(3): 313-315. DOI: 10.16680/j.1671-3826.2017.03.28.
- [109] ZHANG JZ, ZHANG T, GAO X, et al. Clinical research on dual-target alternating intensity modulated radiation therapy combined with Kanglaite for advanced diffused hepatocellular carcinoma[J]. Mod J Integr Tradit Chin West Med, 2019, 28(3): 242-246. DOI: 10.3969/j.issn.1008-8849.2019.03.
- 张江洲, 张拓, 高霞, 等. 双靶区交替调强放疗联合康莱特注射液治疗晚期弥漫型肝癌的临床研究[J]. 现代中西医结合杂志, 2019, 28(3): 242-246. DOI: 10.3969/j.issn.1008-8849.2019.03.
- [110] SUN YH, LI WJ, CUI Y, et al. Effect of Kanglaite injection on AFP-L3, AFP, GP73 and γ -GGT in patients with primary liver cancer[J]. Mod J Integr Tradit Chin West Med, 2020, 29(6): 618-620, 673. DOI: 10.3969/j.issn.1008-8849.2020.06.012.
- 孙艳华, 李伟敬, 崔艳, 等. 康莱特注射液对原发性肝癌患者AFP-L3、AFP、GP73、 γ -GGT的影响[J]. 现代中西医结合杂志, 2020, 29(6): 618-620, 673. DOI: 10.3969/j.issn.1008-8849.2020.06.012.
- [111] KE H, LI XN. The clinical study of iodine-125 seed implantation combined with disodium norcantharidate in the treatment of primary liver cancer[J]. Chin J Surg Oncol, 2016, 8(3): 173-176. DOI: 10.3969/j.issn.1674-4136.2016.03.008.
- 柯怀, 李向农. 碘125粒子植入术联合去甲斑蝥酸钠治疗原发性肝癌[J]. 中国肿瘤外科杂志, 2016, 8(3): 173-176. DOI: 10.3969/j.issn.1674-4136.2016.03.008.
- [112] BAI GD, WU J. Clinical observation of Kangai injection combined with cyberknife in the treatment of 25 cases of primary liver cancer[J]. J N Chin Med, 2012, 44(3): 81-83. DOI: 10.13457/j.cnki.jncm.2012.03.084.
- 白广德, 吴洁. 康艾注射液联合射波刀方案治疗25例原发性肝癌临床观

- 察[J]. 新中医, 2012, 44(3): 81-83. DOI: 10.13457/j.cnki.jncm.2012.03.084.
- [113] LIU JM. Clinical observation of middle-late stage primary hepatic carcinoma patients treated by Disodium Cantharidinate and vitamin B₆ injection combined Cyberknife therapy[J]. J Mod Oncol, 2015, 23(3): 392-394. DOI: 10.3969/j.issn.1672-4992.2015.03.30.
刘建民. 斑蝥酸钠维生素B₆注射液联合射波刀治疗中晚期肝癌临床观察[J]. 现代肿瘤医学, 2015, 23(3): 392-394. DOI: 10.3969/j.issn.1672-4992.2015.03.30.
- [114] GUO HYB, HUANG W, CAO HM, et al. Clinical study of Pien Tze Huang combined with gamma knife surgery in treatment of hepatocellular carcinoma[J]. Chin J Integr Tradit West Med Dig, 2019, 27(10): 735-738, 742. DOI: 10.3969/j.issn.1671-038X.2019.10.04.
郭海渊博, 黄薇, 操黄明, 等. 片仔癀联合伽马刀治疗原发性肝癌的临床研究[J]. 中国中西医结合消化杂志, 2019, 27(10): 735-738, 742. DOI: 10.3969/j.issn.1671-038X.2019.10.04.
- [115] WU GG, ZHAO M. Observation on the effect of Kangai injection combined with chemotherapy in the treatment of advanced liver cancer[J]. J Front Med, 2020, 10(5): 135-136.
吴共国, 赵敏. 康艾注射液联合化疗治疗晚期肝癌效果观察[J]. 医药前沿, 2020, 10(5): 135-136.
- [116] TANG M. Effect of Kang'ai injection combined with chemotherapy on short-term efficacy, immune function and tumor markers in patients with primary liver carcinoma[J]. Chin Foreign Med Res, 2021, 19(22): 148-151. DOI: 10.14033/j.cnki.cfmr.2021.22.052.
唐明. 康艾注射液联合化疗对原发性肝癌患者近期疗效及免疫功能及肿瘤标志物的影响研究[J]. 中外医学研究, 2021, 19(22): 148-151. DOI: 10.14033/j.cnki.cfmr.2021.22.052.
- [117] FU XF, YAN Y, GUO HF. Effects of FOLFOX4 chemotherapy combined with Kang'ai injection on serum AFP, CEA and CA19-9 levels and immune function in patients with primary hepatic carcinoma [J]. Med Innov China, 2022, 19(18): 11-14. DOI: 10.3969/j.issn.1674-4985.2022.18.003.
付先锋, 晏燕, 郭红飞. FOLFOX4 化疗方案联合康艾注射液对原发性肝癌患者血清AFP、CEA和CA19-9水平及免疫功能的影响[J]. 中国医学创新, 2022, 19(18): 11-14. DOI: 10.3969/j.issn.1674-4985.2022.18.003.
- [118] TANG HB. Effect of FOLFOX4 combined with Shenmai injection on the quality of life of patients with advanced liver cancer after operation[J]. J Hepatobiliary Surg, 2016, 24(6): 448-452. DOI: 10.3969/j.issn.1006-4761.2016.06.013.
汤海波. FOLFOX4 联合参麦注射液治疗中晚期肝癌术后存活质量的影响[J]. 肝胆外科杂志, 2016, 24(6): 448-452. DOI: 10.3969/j.issn.1006-4761.2016.06.013.
- [119] YU ZH. Observation on the efficacy and side effects of thalidomide combined with Kanglaite injection in the treatment of primary liver cancer[J/CD]. J Clin Med Lit, 2016, 3(6): 1143, 1146. DOI: 10.16281/j.cnki.jocml.2016.06.111.
于志红. 沙利度胺联合康莱特注射液治疗原发性肝癌的疗效及不良反应观察[J/CD]. 临床医药文献电子杂志, 2016, 3(6): 1143, 1146. DOI: 10.16281/j.cnki.jocml.2016.06.111.
- [120] YE YJ, LU XJ. Curative effect analysis of Kanglaite in the treatment of advanced liver cancer[J]. Shaanxi Oncol Med, 2000, 8(4): 241-242.
叶奕菁, 陆小军. 康莱特治疗晚期肝癌的疗效分析[J]. 陕西肿瘤医学, 2000, 8(4): 241-242.
- [121] LYU YY, ZHONG FZ, ZHANG MY. Therapeutic effect of kanglaite injection combined with chemotherapy on liver cancer[J]. Drug Eval, 2019, 16(16): 54-55. DOI: 10.3969/j.issn.1672-2809.2019.16.027.
吕云勇, 钟方泽, 张明艳. 康莱特注射液配合化疗对肝癌的治疗效果[J]. 药品评价, 2019, 16(16): 54-55. DOI: 10.3969/j.issn.1672-2809.2019.16.027.
- [122] LI Y, ZHAO XM, XU HL, et al. Clinical efficacy and influence of kanglaite combined with chemotherapy on the activity of immune cells in patients with liver cancer[J]. Prog Mod Biomed, 2014, 14(11): 2103-2106. DOI: 10.13241/j.cnki.pmb.2014.11.025.
李颖, 赵兴敏, 徐洪亮, 等. 康莱特注射液配合化疗对肝癌的治疗效果及免疫细胞活性的影响[J]. 现代生物医学进展, 2014, 14(11): 2103-2106. DOI: 10.13241/j.cnki.pmb.2014.11.025.
- [123] LI XY, SHI L, CHENG YH. Study on the therapeutic effect and immune system impact of Kanglaite injection combined with chemotherapy on liver cancer[J]. Mod Digest Interv, 2019(A02): 2100-2101.
李肖芸, 时磊, 程艳会. 康莱特注射液配合化疗对肝癌的疗效及免疫系统的影响研究[J]. 现代消化及介入诊疗, 2019(A02): 2100-2101.
- [124] MA WL, YAN YF, WANG XP. Efficacy of Kanglaite injection combined with chemotherapy for the treatment of hepatocellular carcinoma and its effect on immune system[J]. Int J Immunol, 2017, 40(4): 409-412. DOI: 10.3760/cma.j.issn.1673-4394.2017.04.013.
马文龙, 严亚峰, 王小平. 康莱特注射液配合化疗对肝癌的疗效及免疫系统的影响[J]. 国际免疫学杂志, 2017, 40(4): 409-412. DOI: 10.3760/cma.j.issn.1673-4394.2017.04.013.
- [125] CHEN YL, LI PX. Clinical effect observation of complex sophorae injection combining with chemotherapy on treating liver cancer[J]. J Tianjin Univ Tradit Chin Med, 2006, 25(3): 166-167. DOI: 10.3969/j.issn.1673-9043.2006.03.020.
陈玉兰, 李培训. 复方苦参注射液联合化疗治疗肝癌疗效观察[J]. 天津中医药大学学报, 2006, 25(3): 166-167. DOI: 10.3969/j.issn.1673-9043.2006.03.020.
- [126] SHI L. Clinical effect analysis of compound Sophora flavescens injection in GP regimen chemotherapy for advanced liver cancer[J]. Chin J Mod Drug Appl, 2011, 5(21): 64-65. DOI: 10.14164/j.cnki.cn11-5581/r.2011.21.119.
石磊. 复方苦参注射液在GP方案化疗中晚期肝癌的临床效果分析[J]. 中国现代药物应用, 2011, 5(21): 64-65. DOI: 10.14164/j.cnki.cn11-5581/r.2011.21.119.
- [127] ZHANG XF, ZHOU M. Treatment of 48 cases of primary liver cancer with compound Sophora flavescens injection as adjuvant chemotherapy[J]. Henan Tradit Chin Med, 2014, 34(10): 1929-1930. DOI: 10.16367/j.issn.1003-5028.2014.10.127.
张喜峰, 周敏. 复方苦参注射液辅助化疗治疗原发性肝癌48例[J]. 河南中医, 2014, 34(10): 1929-1930. DOI: 10.16367/j.issn.1003-5028.2014.10.127.
- [128] TIAN YY. Study on the clinical effect of compound Sophora flavescens injection combined with chemotherapy on patients with primary liver cancer[J]. Contemp Med Forum, 2014, 12(19): 45-46.
田元元. 对原发性肝癌患者使用复方苦参注射液联合化疗进行治疗的临床效果研究[J]. 当代医药论丛, 2014, 12(19): 45-46.
- [129] YAO LG. Clinical observation on the treatment of primary liver cancer with compound Kushen injection combined with chemotherapy [J]. Liaoning J Tradit Chin Med, 2015, 42(11): 2145-2146. DOI: 10.13192/j.issn.1000-1719.2015.11.036.
姚丽鸽. 应用复方苦参注射液联合化疗治疗原发性肝癌的临床观察[J]. 辽宁中医杂志, 2015, 42(11): 2145-2146. DOI: 10.13192/j.issn.1000-1719.2015.11.036.
- [130] HE KQ. Application value of compound Kushen injection combined with chemotherapy in the treatment of primary liver cancer[J]. Chin J Clin Ration Drug Use, 2018, 11(20): 51-52. DOI: 10.15887/j.cnki.13-1389/r.2018.20.031.
何克勤. 复方苦参注射液联合化疗治疗原发性肝癌的应用价值[J]. 临床合理用药杂志, 2018, 11(20): 51-52. DOI: 10.15887/j.cnki.13-1389/r.2018.20.031.
- [131] ZHANG DW, HE J, ZHANG HG, et al. Effects of compound Kushen injection in prevention and treatment of recurrence and metastasis of primary hepatic cellular carcinoma and the effect on serum P53 antibody, VEGF, TGF- β 1 and Ki67 levels[J]. World Chin Med, 2018, 13(3): 601-604. DOI: 10.3969/j.issn.1673-7202.2018.03.013.
张大为, 何津, 张海光, 等. 复方苦参注射液防治原发性肝癌复发转移的

- 临床效果[J]. 世界中医药, 2018, 13(3): 601-604. DOI: 10.3969/j.issn.1673-7202.2018.03.013.
- [132] ZHENG WD, ZHENG DH, ZHENG WH. Clinical summarization of "cidan capsule" in treating 325 cases of primary liver cancer[J]. Shanghai J Tradit Chin Med, 2002, 36(12): 7-8. DOI: 10.16305/j.1007-1334.2002.12.003.
郑伟达, 郑东海, 郑伟鸿. 慈丹胶囊治疗原发性肝癌 325 例临床总结[J]. 上海中医药杂志, 2002, 36(12): 7-8. DOI: 10.16305/j.1007-1334.2002.12.003.
- [133] WANG JX, ZHOU CF, ZHENG WD. Clinical effect of cidan capsule on patients with primary hepatocellular carcinoma[J]. World J Integr Tradit West Med, 2006, 1(3): 160-162. DOI: 10.3969/j.issn.1673-6613.2006.03.012.
王俊显, 周超凡, 郑伟达. 慈丹胶囊治疗原发性肝癌的临床疗效观察[J]. 世界中西医结合杂志, 2006, 1(3): 160-162. DOI: 10.3969/j.issn.1673-6613.2006.03.012.
- [134] XU X, ZHENG WH, ZHENG DH, et al. Clinical observation on the treatment of 150 cases of primary liver cancer with cidan capsules [C]//2011 China Famous Chinese Medicine Forum & Summit Forum on Prevention and Treatment of Cancer by Taking Advantages of Traditional Chinese and Western Medicine, Fuzhou, 2011: 204-207.
许鑫, 郑伟鸿, 郑东海, 等. 慈丹胶囊治疗原发性肝癌 150 例临床观察 [C]//2011 年中华名中医论坛暨发挥中西医优势防治肿瘤高峰论坛论文集, 福州, 2011: 204-207.
- [135] CHENG HW, LUO ML, JIANG T, et al. Effect of Aidi injection combined with FOLFOX4 chemotherapy in the treatment of primary liver cancer[J]. J Mod Oncol, 2012, 20(4): 777-779. DOI: 10.3969/j.issn.1672-4992.2012.04.37.
程宏文, 骆明莲, 江涛, 等. 艾迪注射液联合 FOLFOX4 化疗治疗原发性肝癌疗效观察[J]. 现代肿瘤医学, 2012, 20(4): 777-779. DOI: 10.3969/j.issn.1672-4992.2012.04.37.
- [136] WANG CZ. Clinical observation of Aidi injection combined with chemotherapy in the treatment of primary liver cancer[J]. Mod Diagn Treat, 2016, 27(24): 4634-4635. DOI: 10.3969/j.issn.1001-8174.2016.24.029.
王承志. 艾迪注射液联合化疗治疗原发性肝癌的临床疗效观察[J]. 现代诊断与治疗, 2016, 27(24): 4634-4635. DOI: 10.3969/j.issn.1001-8174.2016.24.029.
- [137] HOU CW, ZHENG LM, ZHAO L, et al. Effects of aidi injection combined with 5-fluorouracil on T lymphocyte subsets in patients with primary hepatocellular carcinoma[J]. Pract J Cancer, 2017, 32(11): 1851-1854. DOI: 10.3969/j.issn.1001-5930.2017.11.033.
侯传伟, 郑黎明, 赵雷, 等. 艾迪注射液联合 5-氟尿嘧啶对原发性肝癌患者 T 淋巴细胞亚群的影响[J]. 实用癌症杂志, 2017, 32(11): 1851-1854. DOI: 10.3969/j.issn.1001-5930.2017.11.033.
- [138] HOU YL. Effect of Aidi injection combined with CAFI chemotherapy on KPS score and tumor disease control rate of patients with primary liver cancer[J]. J N Pharm, 2018, 15(7): 56-57. DOI: 10.3969/j.issn.1672-8351.2018.07.042.
侯艳林. 艾迪注射液联合 CAFI 化疗方案对原发性肝癌患者 KPS 评分及肿瘤疾病控制率的影响[J]. 北方药学, 2018, 15(7): 56-57. DOI: 10.3969/j.issn.1672-8351.2018.07.042.
- [139] ZHANG Q. Effect of aidi injection combined with XELOX chemotherapy on serum AFP and CEA levels in patients with primary hepatocellular carcinoma[J]. Mod Diagn Treat, 2018, 4(21): 3398-3400.
张琪. 艾迪注射液联合 XELOX 化疗方案对原发性肝癌患者血清 AFP、CEA 水平变化的影响[J]. 现代诊断与治疗, 2018, 4(21): 3398-3400.
- [140] ZHANG MM. Effect of Aidi injection combined with XELOX chemotherapy regimen on serum VEGF and ICAM-1 levels in patients with primary liver cancer[J]. Henan Med Res, 2018, 27(5): 819-820.
张苗苗. 艾迪注射液联合 XELOX 化疗方案对原发性肝癌患者血清 VEGF、ICAM-1 水平的影响[J]. 河南医学研究, 2018, 27(5): 819-820.
- [141] YANG BF. Therapeutic effect of aidi injection combined with HLF chemotherapy on liver cancer[J]. World J Complex Med, 2018, 4(3): 51-53. DOI: 10.11966/j.issn.2095-994X.2018.04.03.17.
杨斌峰. 艾迪注射液联合 HLF 化疗方案治疗肝癌疗效分析[J]. 世界复合医学, 2018, 4(3): 51-53. DOI: 10.11966/j.issn.2095-994X.2018.04.03.17.
- [142] HAN Y. Clinical effect of Aidi injection combined with XELOX chemotherapy in the treatment of advanced primary liver cancer[J]. Henan Med Res, 2020, 29(8): 1439-1440. DOI: 10.3969/j.issn.1004-437X.2020.08.047.
韩瑜. 艾迪注射液联合 XELOX 化疗治疗晚期原发性肝癌的临床效果[J]. 河南医学研究, 2020, 29(8): 1439-1440. DOI: 10.3969/j.issn.1004-437X.2020.08.047.
- [143] WANG GQ, LI XX, NIU YL, et al. Effect of Aidi injection combined with FOLFOX4 chemotherapy regimen in treating hepatocellular carcinoma and its influence on inflammatory factors and hydrogen sulphide in serum[J]. China Med, 2015, 10(12): 1775-1778. DOI: 10.3760/cma.j.issn.1673-4777.2015.12.013.
王国强, 李晓霞, 牛业来, 等. 艾迪注射液联合 FOLFOX4 方案治疗原发性肝癌的效果观察及对血清炎症因子和硫化氢水平的影响[J]. 中国医药, 2015, 10(12): 1775-1778. DOI: 10.3760/cma.j.issn.1673-4777.2015.12.013.
- [144] WU J, SHEN HD. Pill of DaHuang ZheChongWan with chemotherapy in the treatment of primary carcinoma of liver at middle-advanced stage[J]. West J Tradit Chin Med, 2011, 24(10): 54-55. DOI: 10.3969/j.issn.1004-6852.2011.10.022.
吴洁, 申弘道. 大黄蟾虫丸联合化疗治疗中晚期原发性肝癌的临床观察[J]. 西部中医药, 2011, 24(10): 54-55. DOI: 10.3969/j.issn.1004-6852.2011.10.022.
- [145] ZHOU L. Clinical observation of Dahuangzhechong pill combined with gemcitabine and oxaliplatin in the treatment of primary liver cancer[J]. J N Chin Med, 2014, 46(2): 161-163. DOI: 10.13457/j.cnki.jncm.2014.02.092.
周利. 大黄蟾虫丸联合吉西他滨及奥沙利铂方案治疗原发性肝癌临床观察[J]. 新中医, 2014, 46(2): 161-163. DOI: 10.13457/j.cnki.jncm.2014.02.092.
- [146] YANG JM, HE YH, MA BM. DaHuang ZheChong pills combined with chemotherapy in treating 35 cases of primary liver cancer[J]. West J Tradit Chin Med, 2018, 4(10): 83-85.
杨军民, 何耀辉, 马宝梅. 大黄[庶虫]虫丸联合化疗治疗原发性肝癌 35 例[J]. 西部中医药, 2018, 4(10): 83-85.
- [147] XIA NX, QIU BA, WANG JH, et al. Chemotherapy combined with Huaier Granule in the prognosis of patients with recurrent/metastatic after primary hepatocellular carcinoma[J]. Clin J Med Off, 2017, 45(9): 887-890. DOI: 10.16680/j.1671-3826.2017.09.03.
夏念信, 邱宝安, 王敬晗, 等. 化疗联合槐耳颗粒对原发性肝癌术后复发/转移患者预后影响研究[J]. 临床军医杂志, 2017, 45(9): 887-890. DOI: 10.16680/j.1671-3826.2017.09.03.
- [148] ZHU L, HUANG Y. Clinical observation of Huaier Granule combined with improved FOLFOX regimen in the treatment of advanced liver cancer[J]. Guide China Med, 2017, 15(3): 188. DOI: 10.15912/j.cnki.gocm.2017.03.152.
朱琳, 黄英. 槐耳颗粒联合改良 FOLFOX 方案治疗中晚期肝癌的临床疗效观察[J]. 中国医药指南, 2017, 15(3): 188. DOI: 10.15912/j.cnki.gocm.2017.03.152.
- [149] LIU GD, XIAO GL. Effects of Shengqi fuzheng injection combined chemotherapy on patients with primary liver cancer[J]. Prog Mod Biomed, 2010, 10(7): 1348-1350. DOI: 10.13241/j.cnki.pmb.2010.07.041.
刘国栋, 肖桂林. 参芪扶正注射液联合化疗治疗原发性肝癌的临床疗效观察[J]. 现代生物医学进展, 2010, 10(7): 1348-1350. DOI: 10.13241/j.cnki.pmb.2010.07.041.
- [150] HAN LJ, ZHANG HX, XU HJ, et al. Effects of oxaliplatin and Shenqi fuzheng injection on serum levels of afp and GP73 in patients with primary liver cancer and its clinical efficacy[J]. Prog Mod Biomed,

- 2016, 16(22): 4289-4291, 4366. DOI: 10.13241/j.cnki.pmb.2016.22.022.
- 韩鲁军, 张红欣, 许会军, 等. 奥沙利铂联合参芪扶正注射液对原发性肝癌患者AFP与GP73水平的影响及临床疗效[J]. 现代生物医学进展, 2016, 16(22): 4289-4291, 4366. DOI: 10.13241/j.cnki.pmb.2016.22.022.
- [151] TIAN SY, XU AB, HUANG HH, et al. Clinical observation of cinobufotalin combined with FOLFOX4 regimen in the treatment of 60 cases of advanced liver cancer[J]. J China Prescr Drug, 2016, 14(11): 72-73. DOI: 10.3969/j.issn.1671-945X.2016.11.053.
- 田思源, 徐爱兵, 黄洪华, 等. 华蟾素联合FOLFOX4方案治疗中晚期肝癌60例疗效观察[J]. 中国处方药, 2016, 14(11): 72-73. DOI: 10.3969/j.issn.1671-945X.2016.11.053.
- [152] SHU XH, TAN BX. Short-term efficacy of cinobufotalin combined with 5-fluorouracil in the treatment of advanced liver cancer[J]. Sichuan J Cancer Contr, 2004, 17(2): 88-89. DOI: 10.3969/j.issn.1674-0904.2004.02.010.
- 舒小红, 谭榜宪. 华蟾素联合5-氟脲嘧啶治疗中晚期肝癌近期疗效观察[J]. 四川肿瘤防治, 2004, 17(2): 88-89. DOI: 10.3969/j.issn.1674-0904.2004.02.010.
- [153] LAI YQ, JIN Y, CHEN YY. Clinical analysis of cinobufotalin combined with chemotherapy in the treatment of advanced liver cancer[J]. Shaanxi Oncol Med, 2002, 10(3): 217.
- 赖义勤, 金源, 陈云莺. 华蟾素配合化疗治疗中晚期肝癌临床分析[J]. 陕西肿瘤医学, 2002, 10(3): 217.
- [154] SHAO YX, MAO H. Effect of Brucea javanica oil soft capsule combined with XELOX chemotherapy on liver function and quality of life of patients with advanced liver cancer[J]. J Med Theory Pract, 2020, 33(4): 590-591. DOI: 10.19381/j.issn.1001-7585.2020.04.035.
- 邵玉香, 毛辉. 鸦胆子油软胶囊联合XELOX化疗方案对晚期肝癌患者肝功能及生存质量的影响[J]. 医学理论与实践, 2020, 33(4): 590-591. DOI: 10.19381/j.issn.1001-7585.2020.04.035.
- [155] PENG WD. Clinical observation of compound mylabris capsule combined with chemotherapy in the treatment of advanced primary liver cancer[J]. Guid J Tradit Chin Med Pharm, 2011, 17(10): 39-40. DOI: 10.13862/j.cnki.cn43-1446/r.2011.10.059.
- 彭文达. 复方斑蝥胶囊联合化疗治疗中晚期原发性肝癌的临床观察[J]. 中医药导报, 2011, 17(10): 39-40. DOI: 10.13862/j.cnki.cn43-1446/r.2011.10.059.
- [156] TENG WF, MAO QQ, YU DS, et al. Clinical effects of Xiaozheng Yigan Tablet combined with mFOLFOX6 regimen in treatment of advanced primary liver cancer[J]. Chin Arch Tradit Chin Med, 2020, 38(4): 204-208. DOI: 10.13193/j.issn.1673-7717.2020.04.048.
- 滕伟峰, 毛琦琪, 俞丹松, 等. 消瘕益肝片联合mFOLFOX6方案治疗晚期原发性肝癌临床研究[J]. 中华中医药学刊, 2020, 38(4): 204-208. DOI: 10.13193/j.issn.1673-7717.2020.04.048.
- [157] TANG YF, ZHU XJ, HUANG LY, et al. Clinical study on Huaier Granules combined with sorafenib in treatment of advanced liver cancer[J]. Drugs Clin, 2018, 33(7): 1732-1735. DOI: 10.7501/j.issn.1674-5515.2018.07.039.
- 唐亦非, 朱晓骏, 黄凌鹰, 等. 槐耳颗粒联合索拉非尼治疗晚期肝癌的临床研究[J]. 现代药物与临床, 2018, 33(7): 1732-1735. DOI: 10.7501/j.issn.1674-5515.2018.07.039.
- [158] YANG YS, YANG YL, ZHANG M, et al. Clinical observation of Huachansu Capsule combined with sorafenib tosylate in the treatment of primary liver cancer with bone metastasis[J/CD]. Mod Med Health Res, 2019, 3(5): 1-3, 9.
- 杨永生, 杨元磊, 张梅, 等. 华蟾素胶囊联合甲苯磺酸索拉非尼片治疗原发性肝癌伴骨转移的临床观察[J/CD]. 现代医学与健康研究电子杂志, 2019, 3(5): 1-3, 9.
- [159] FENG LH, CHEN YD, ZHENG ZG, et al. Clinical observation of patients with primary liver cancer treated by sorafenib combined cinobufagin tablets[J]. China Oncol, 2012, 22(11): 856-859. DOI: 10.3969/j.issn.1007-3969.2012.11.010.
- 冯丽华, 陈毅德, 郑志高, 等. 索拉非尼联合华蟾素片治疗中晚期原发性肝癌的临床疗效观察[J]. 中国癌症杂志, 2012, 22(11): 856-859. DOI: 10.3969/j.issn.1007-3969.2012.11.010.
- [160] WANG YD, DING HB, HUANG ZC, et al. Short-term efficacy observation of intravenous administration of cinobufalin combined with lenvatinib in the treatment of primary liver cancer patients after TACE[J]. J Clin Res, 2022, 8(1): 9-12. DOI: 10.3969/j.issn.1671-7171.2022.01.003.
- 王颖栋, 丁海斌, 黄子超, 等. 华蟾素联合仑伐替尼治疗经动脉化疗栓塞术后原发性肝癌患者的近期疗效[J]. 医学临床研究, 2022, 8(1): 9-12. DOI: 10.3969/j.issn.1671-7171.2022.01.003.
- [161] LU Y, QI Y. Clinical efficacy and liver function analysis of elemene injection combined with sorafenib in the treatment of liver cancer patients[J]. J Med Theory Pract, 2019, 32(20): 3292-3293. DOI: 10.19381/j.issn.1001-7585.2019.20.037.
- 陆颖, 齐艳. 榄香烯注射液联合索拉非尼治疗肝癌患者临床疗效及肝功能分析[J]. 医学理论与实践, 2019, 32(20): 3292-3293. DOI: 10.19381/j.issn.1001-7585.2019.20.037.
- [162] SUN J, ZHANG F. Effect of elemene injection combined with molecular targeting drugs on immunity and survival status of patients with liver cancer metastasis[J]. Chin J Integr Tradit West Med Liver Dis, 2022, 32(1): 16-19. DOI: 10.3969/j.issn.1005-0264.2022.01.004.
- 孙静, 张峰. 榄香烯注射液联合分子靶向药物对肝癌转移患者免疫力及生存期的影响[J]. 中西医结合肝病杂志, 2022, 32(1): 16-19. DOI: 10.3969/j.issn.1005-0264.2022.01.004.
- [163] WEI J, NI LG, CHEN XM, et al. Study on the curative effect of Jiedu Huoxue Decoction combined with spleen polypeptide injection and apatinib in the treatment of advanced liver cancer[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31(9): 803-805. DOI: 10.3969/j.issn.1005-0264.2021.09.009.
- 魏娟, 倪龙刚, 陈贤明, 等. 参芪扶正注射液联合阿帕替尼和脾多肽注射液治疗晚期原发性肝癌患者的临床研究[J]. 中西医结合肝病杂志, 2021, 31(9): 803-805. DOI: 10.3969/j.issn.1005-0264.2021.09.009.
- [164] HAO WJ. Effect of adjuvant therapy of Shenqi fuzheng injection on the clinical efficacy and immune function of patients with advanced primary liver cancer[J]. China J Pharm Econ, 2020, 15(8): 71-73, 78. DOI: 10.12010/j.issn.1673-5846.2020.08.016.
- 郝文杰. 参芪扶正注射液辅助治疗对晚期原发性肝癌患者临床疗效和免疫功能的影响[J]. 中国药物经济学, 2020, 15(8): 71-73, 78. DOI: 10.12010/j.issn.1673-5846.2020.08.016.
- [165] LIU DM, ZHANG J, ZHANG BB, et al. Effect of Shenqi fuzheng injection combined with sorafenib on advanced primary liver cancer and its effect on VEGF, TNF- α and IFN- γ levels in patients[J]. Prog Mod Biomed, 2019, 19(22): 4287-4290, 4334. DOI: 10.13241/j.cnki.pmb.2019.22.018.
- 刘东梅, 张剑, 张兵兵, 等. 参芪扶正注射液联合索拉非尼对晚期原发性肝癌的疗效及对患者VEGF、TNF- α 、IFN- γ 水平的影响[J]. 现代生物医学进展, 2019, 19(22): 4287-4290, 4334. DOI: 10.13241/j.cnki.pmb.2019.22.018.
- [166] LU XY, HUA GD, BAI J, et al. Effect of Shenqi Fuzheng injection combined with sorafenib on miR-103, CXCR3 and AFP in postoperative patients with liver cancer[J]. Chin J Integr Tradit West Med Liver Dis, 2020, 30(3): 218-220, 230, 290. DOI: 10.3969/j.issn.1005-0264.2020.03.009.
- 陆晓怡, 华国栋, 白洁, 等. 参芪扶正注射液联合索拉非尼对肝癌术后患者微小RNA-103、趋化因子受体及甲胎蛋白的影响[J]. 中西医结合肝病杂志, 2020, 30(3): 218-220, 230, 290. DOI: 10.3969/j.issn.1005-0264.2020.03.009.
- [167] WANG PP. Systematic review and reticular meta-analysis of traditional Chinese medicine injection combined Meta cisplatin intraperitoneal perfusion in the treatment of cancerous ascites[D]. Beijing: Beijing University of Chinese Medicine, 2020. DOI: 10.26973/d.cnki.gbjzu.2020.000328.

- 王佩佩. 中药注射液联合顺铂腹腔灌注治疗癌性腹水的系统评价和网状Meta分析[D]. 北京: 北京中医药大学, 2020.
- [168] CHEN ZC. Clinical effect of Kangai injection combined with chemotherapy in the treatment of cancer-related fatigue of hepatocellular carcinoma patients[J]. *Int J Transplant Hemopurification*, 2017, 15(6): 39-41. DOI: 10.3760/cma.j.issn.1673-4238.2017.06.010. 陈志成. 康艾注射液联合化疗治疗肝癌因性疲乏的临床效果[J]. *国际移植与血液净化杂志*, 2017, 15(6): 39-41. DOI: 10.3760/cma.j.issn.1673-4238.2017.06.010.
- [169] WANG XT, ZHANG CL, CHEN XQ, et al. Efficacy of cinobufotalin for the treatment of primary liver cancer-related pain[J]. *Health Med Res Pract*, 2018, 15(6): 36-39. DOI: 10.11986/j.issn.1673-873X.2018.06.009. 王新亭, 张传雷, 陈晓琦, 等. 华蟾素治疗原发性肝癌癌性疼痛的效果观察[J]. *保健医学研究与实践*, 2018, 15(6): 36-39. DOI: 10.11986/j.issn.1673-873X.2018.06.009.
- [170] XIAO MZ, JIANG MH, SHAO DS. The clinical application of external therapy of traditional Chinese medicine in patients with advanced liver cancer[C]. *Suzhou*, 2014: 285-287. 肖明中, 蒋满红, 邵冬珊. 中医外治法在肝癌晚期患者中的临床应用[C]. *苏州*, 2014: 285-287.
- [171] HUANG XX, ZHOU CJ, LIN LJ, et al. Effect of Dahuang Fuzi Xixin Decoction Enema on gastrointestinal dysfunction after laparoscopic hepatocellular carcinoma[J]. *Chin J Surg Integr Tradit West Med*, 2022, 28(4): 456-459. DOI: 10.3969/j.issn.1007-6948.2022.04.004. 黄晓璇, 周春姣, 林丽君, 等. 大黄附子细辛汤灌肠治疗腹腔镜肝癌术后胃肠功能障碍的临床疗效[J]. *中国中西医结合外科杂志*, 2022, 28(4): 456-459. DOI: 10.3969/j.issn.1007-6948.2022.04.004.
- [172] CHEN Y, WANG Y, DENG RB, et al. Observation on therapeutic effect of colon dialysis sequential enema with traditional Chinese medicine on early postoperative inflammatory intestinal obstruction of primary liver cancer[J]. *J Sichuan Tradit Chin Med*, 2017, 35(8): 161-163. 陈勇, 王勇, 邓如兵, 等. 结肠透析序贯中药灌肠治疗原发性肝癌术后早期炎性肠梗阻疗效观察[J]. *四川中医*, 2017, 35(8): 161-163.
- [173] HUANG CQ, LIAO LL, TENG YJ, et al. Observation on the effect of Zusanli acupoint application combined with auricular point pressing in the treatment of abdominal distension after primary liver cancer surgery[J]. *Diet Health*, 2018, 5(6): 97-98. 黄楚青, 廖黎黎, 滕艳娟, 等. 足三里穴位敷贴联合耳穴按压治疗原发性肝癌术后腹胀的效果观察[J]. *饮食保健*, 2018, 5(6): 97-98.
- [174] PANG ZF, YAN XN. The effect of Zusanli acupoint application combined with auricular point pressing on reducing the degree of abdominal distension after liver cancer surgery[J]. *Chin Health Care*, 2020, 6(12): 112-113. 庞增粉, 闫晓宁. 足三里穴位敷贴联合耳穴按压减轻肝癌术后腹胀程度的效果[J]. *中华养生保健*, 2020, 38(12): 112-113.
- [175] LYU F, FU XP, LIU XM, et al. Clinical observation on Zusanli acupoint application combined with auricular point pressing in the treatment of abdominal distension after primary liver cancer operation[J]. *Guangming J Chin Med*, 2021, 36(14): 2303-2305. DOI: 10.3969/j.issn.1003-8914.2021.14.011. 吕芳, 付雪平, 刘心梅, 等. 足三里穴位敷贴联合耳穴按压治疗原发性肝癌术后腹胀临床观察[J]. *光明中医*, 2021, 36(14): 2303-2305. DOI: 10.3969/j.issn.1003-8914.2021.14.011.
- [176] YAO XY, FAN BF. Analysis of the effect of Zusanli acupoint application combined with auricular point pressing beans on improving abdominal distension after primary liver cancer surgery[J]. *Health Required*, 2021, 29: 252. 姚小燕, 范本芳. 足三里穴位敷贴联合耳穴压豆改善原发性肝癌术后腹胀的效果分析[J]. *健康必读*, 2021, 29: 252.
- [177] PANG ZF. Effect of acupoint application on nausea, vomiting and quality of life of patients with liver cancer after operation based on the concept of rapid rehabilitation[J]. *Int J Nurs*, 2022, 41(11): 2064-2068. DOI: 10.3760/cma.j.cn221370-20201230-00532. 庞增粉. 基于快速康复理念的肝癌患者术后行穴位贴敷对患者恶心呕吐及生活质量的影响[J]. *国际护理学杂志*, 2022, 41(11): 2064-2068. DOI: 10.3760/cma.j.cn221370-20201230-00532.
- [178] ZHANG SK, GAO WB, LIU Y, et al. Therapeutic effect of cervical Jiaji electroacupuncture on postoperative intractable hiccup of liver neoplasms[J]. *Chin J Oncol*, 2018, 40(2): 138-140. DOI: 10.3760/cma.j.issn.0253-3766.2018.02.011. 张世科, 高维滨, 刘勇, 等. 电针颈夹脊穴治疗肝癌切除术后顽固性呃逆的疗效观察[J]. *中华肿瘤杂志*, 2018, 40(2): 138-140. DOI: 10.3760/cma.j.issn.0253-3766.2018.02.011.
- [179] YANG DJ. The Clinical Study of Auricular Point Pressing Therapy on Patients with Sleep Disorder after Laparoscopic Primary Hepatocellular Carcinoma Resection[D]. *Guangzhou: Guangzhou University of Chinese Medicine*, 2020. DOI: 10.27044/d.cnki.ggz.2020.000357. 杨达钧. 耳穴贴压治疗腹腔镜原发性肝癌切除术后患者睡眠障碍的临床研究[D]. *广州: 广州中医药大学*, 2020. DOI: 10.27044/d.cnki.ggz.2020.000357.
- [180] LIU LL, XIA M, LEI YC, et al. Study on auricular seeds taping therapy intervening sleep disorder in patients with primary liver cancer[J]. *J Guangxi Univ Nat Sci Ed*, 2020, 45(3): 717-722. DOI: 10.13624/j.cnki.issn.1001-7445.2020.0717. 柳琳琳, 夏猛, 雷雨迟, 等. 耳穴压豆治疗肝癌患者睡眠障碍的研究[J]. *广西大学学报(自然科学版)*, 2020, 45(3): 717-722. DOI: 10.13624/j.cnki.issn.1001-7445.2020.0717.
- [181] XIE J, CHEN LH, NING ZY, et al. Effect of transcutaneous electrical acupoint stimulation combined with palonosetron on chemotherapy-induced nausea and vomiting: A single-blind, randomized, controlled trial[J]. *Chin J Cancer*, 2017, 36(1): 6. DOI: 10.1186/s40880-016-0176-1.
- [182] DU TF. Observation of the Clinical Effect of Treating Primaryliver Cancer with Ascites by Shipixiaoshui Cream Formula External Application[D]. *Urumqi: Xinjiang Medical University*, 2017. 杜腾飞. 实脾消水膏外敷治疗原发性肝癌腹水的临床疗效观察[D]. *乌鲁木齐: 新疆医科大学*, 2017.
- [183] ZHAO B, LIU YC. Observation on therapeutic effect of mirabilite external application on ascites due to liver cancer[J]. *J Pract Tradit Chin Med*, 2014, 30(4): 330. DOI: 10.3969/j.issn.1004-2814.2014.04.058. 赵冰, 刘颖春. 芒硝外敷治疗肝癌腹水疗效观察[J]. *实用中医药杂志*, 2014, 30(4): 330. DOI: 10.3969/j.issn.1004-2814.2014.04.058.
- [184] XIONG YH, LIU WQ. 25 cases of abdominal effusion treated by external application of Xingqi Lishui ointment combined with hyperthermia[J]. *Zhejiang J Tradit Chin Med*, 2013, 48(8): 563. DOI: 10.3969/j.issn.0411-8421.2013.08.012. 熊翊兹, 刘文奇. 行气利水膏外敷联合热疗治疗腹腔积液 25 例[J]. *浙江中医杂志*, 2013, 48(8): 563. DOI: 10.3969/j.issn.0411-8421.2013.08.012.
- [185] YAN YC. Randomized controlled clinical study on moxibustion intervention in moderate and severe cancer-related fatigue in patients with liver cancer[D]. *Shanghai: Shanghai University of Traditional Chinese Medicine*, 2016. 严一成. 艾灸干预肝癌患者中重度癌因性疲乏随机对照临床研究[D]. *上海: 上海中医药大学*, 2016.
- [186] ZHANG K, HAN Q, ZHAO LN. Effect of moxibustion on quality of life in patients with advanced liver cancer [J]. *Healthmust-Readmagazine*, 2021, 2: 174. 张坤, 韩倩, 赵丽娜. 艾灸对晚期肝癌患者生存质量影响[J]. *健康必读*, 2021, 2: 174.
- [187] YU WF, SHEN HJ. Curative effect observation and nursing experience on acupoint application of Chinese herbs for liver cancer pain [J]. *J N Chin Med*, 2018, 50(12): 245-248. DOI: 10.13457/j.cnki.jncm.2018.12.073.

- 俞文方, 沈华江. 中药穴位贴敷治疗肝癌癌痛疗效观察与护理体会[J]. 新中医, 2018, 50(12): 245-248. DOI: 10.13457/j.cnki.jncm.2018.12.073.
- [188] ZHOU DQ, ZHOU TH, WANG X, et al. Observation on therapeutic effect of acupoint application of Aitong plaster on cancer pain of primary liver cancer[J]. J Front Med, 2016, 6(11): 325-326.
- 周德奇, 周天寒, 汪霞, 等. 癌痛贴穴位贴敷治疗原发性肝癌癌性疼痛的疗效观察[J]. 医药前沿, 2016, 6(11): 325-326.
- [189] YOU Y. Effects of acupoint application of traditional Chinese medicine combined with Morphine on pain and adverse reactions in patients with advanced liver cancer[J]. Med J Chin People's Health, 2021, 33(2): 83-85. DOI: 10.3969/j.issn.1672-0369.2021.02.032.
- 尤义. 中药穴位贴敷联合吗啡对晚期肝癌患者疼痛及不良反应的影响[J]. 中国民康医学, 2021, 33(2): 83-85. DOI: 10.3969/j.issn.1672-0369.2021.02.032.
- [190] GEN JY. Observation and experience of curative effect of acupoint application of traditional Chinese medicine on liver cancer pain [J]. World Latest Med Inf, 2021, 21(16): 277-278. DOI: 10.3969/j.issn.1671-3141.2021.16.136.
- 巩金艳. 中药穴位贴敷治疗肝癌癌痛的疗效观察与体会[J]. 世界最新医学信息文摘, 2021, 21(16): 277-278. DOI: 10.3969/j.issn.1671-3141.2021.16.136.
- [191] ZHANG YY. Analysis of the intervention effect of acupoint application of traditional Chinese medicine on pain in patients with primary liver cancer[J]. J Clin Nursing's Pract, 2017, 2(18): 128, 134. DOI: 10.3969/j.issn.2096-2479.2017.18.098.
- 张燕燕. 中药穴位贴敷对原发性肝癌患者疼痛的干预效果分析[J]. 实用临床护理学电子杂志, 2017, 2(18): 128, 134. DOI: 10.3969/j.issn.2096-2479.2017.18.098.
- [192] LI Q. Observation on therapeutic effect of acupoint application on pain of advanced liver cancer[J]. Shanxi J Tradit Chin Med, 2015, 31(3): 45, 57.
- 李琪. 穴位贴敷治疗中晚期肝癌疼痛疗效观察[J]. 山西中医, 2015, 31(3): 45, 57.
- [193] WANG LL. Systematic evaluation of the clinical efficacy of external application of Chinese medicine to treat primary liver cancer pain [D]. Jinan: Shandong University of Traditional Chinese Medicine, 2020. DOI: 10.27282/d.cnki.gsdzu.2020.000375.
- 王璐璐. 中药外敷治疗原发性肝癌疼痛临床疗效的系统评价[D]. 济南: 山东中医药大学, 2020. DOI: 10.27282/d.cnki.gsdzu.2020.000375.
- [194] ZHANG XW, GU YJ, WU HG, et al. Systematic Review and Meta-Analysis of Acupuncture for Pain Caused by Liver Cancer [J]. World J Tradit Chin Med, 2022, 3:402-412.
- [195] LIU LX. The curative effect of thermal moxibustion in the adjuvant treatment of moderate liver cancer pain and its effect on TNF- α and IL-2 [J]. Shanghai J Acupunct Moxib, 2020, 39(6): 692-696. DOI: 10.13460/j.issn.1005-0957.2020.06.0692.
- 刘丽霞. 热敏灸辅助治疗中度肝癌痛的疗效及对 TNF- α 、IL-2 的影响[J]. 上海针灸杂志, 2020, 39(6): 692-696. DOI: 10.13460/j.issn.1005-0957.2020.06.0692.
- [196] XU L, BAO JF, YU HY, et al. Effect of auricular point pressure bean on perioperative pain and anxiety in patients with liver cancer undergoing interventional therapy[J]. China Mod Dr, 2018, 56(33): 98-101.
- 徐蕾, 包剑锋, 俞海燕, 等. 耳穴压豆对肝癌介入治疗患者围手术期疼痛及焦虑的影响[J]. 中国现代医生, 2018, 56(33): 98-101.
- [197] XIN CC, LI SH, WANG M, et al. Analysis of influencing factors on hope level and spiritual health of patients with liver cancer[J]. J Qilu Nurs, 2022, 28(12): 52-55. DOI: 10.3969/j.issn.1006-7256.2022.12.017.
- 辛翠翠, 李士红, 王敏, 等. 肝癌患者希望水平与灵性健康的影响因素分析[J]. 齐鲁护理杂志, 2022, 28(12): 52-55. DOI: 10.3969/j.issn.1006-7256.2022.12.017.
- [198] Hematology Branch of Chinese Association of Chinese Medicine. Experts consensus on TCM diagnosis and treatment for tumor related depressive status[J]. China J Tradit Chin Med Pharm, 2015, 30(12): 4397-4399.
- 中华中医药学会血液病分会. 肿瘤相关抑郁状态中医诊疗专家共识[J]. 中华中医药杂志, 2015, 30(12): 4397-4399.
- [199] XIAO J, WANG J, NIU Y. Effect of emotional conditioning combined with Baduanjin in patients with liver cancer treated with chemotherapy[J]. Henan Med Res, 2023, 32(15): 2850-2854.
- 肖静, 王静, 牛颖. 情志调理联合八段锦对肝癌化疗患者的影响[J]. 河南医学研究, 2023, 32(15): 2850-2854.
- [200] WANG YZ. Diet strategy for patients with liver cancer[J]. Food Health, 2023, 35(4): 18-20.
- 王毅州. 肝癌患者饮食全攻略[J]. 食品与健康, 2023, 35(4): 18-20.
- [201] CAMPBELL KL, WINTERS-STONE KM, WISKEMANN J, et al. Exercise guidelines for cancer survivors: Consensus statement from international multidisciplinary roundtable[J]. Med Sci Sports Exerc, 2019, 51(11): 2375-2390. DOI: 10.1249/MSS.0000000000002116.
- [202] YU KT, JIA J. Hepatocellular carcinoma related guidelines and expert consensus interpretation from the perspective of full cycle rehabilitation[J]. Chin J Med, 2022, 57(1): 18-21. DOI: 10.3969/j.issn.1008-1070.2022.01.006.
- 余恺涛, 贾杰. 全周期康复视角下的肝癌相关指南及专家共识解读[J]. 中国医刊, 2022, 57(1): 18-21. DOI: 10.3969/j.issn.1008-1070.2022.01.006.
- [203] Chinese Society of Hepatology, Chinese Medical Association. The consensus on tertiary prevention of primary liver cancer (2022 version) [J]. Chin J Hepatol, 2022, 30(8): 832-845. DOI: 10.3760/cma.j.cn501113-20220616-00330.
- 中华医学会肝病学会. 原发性肝癌三级预防共识(2022年版)[J]. 中华肝脏病杂志, 2022, 30(8): 832-845. DOI: 10.3760/cma.j.cn501113-20220616-00330.
- [204] Prevention of Infection Related Cancer (PIRCA) Group, Specialized Committee of Cancer Prevention and Control, Chinese Preventive Medicine Association; Non-communicable & Chronic Disease Control and Prevention Society, Chinese Preventive Medicine Association; Health Communication Society, Chinese Preventive Medicine Association. Strategies of primary prevention of liver cancer in China: Expert Consensus(2018) [J]. J Clin Hepatol, 2018, 34(10): 2090-2097. DOI: 10.3969/j.issn.1001-5256.2018.10.008.
- 中华预防医学会肿瘤预防与控制专业委员会感染相关肿瘤防控学组, 中华预防医学会慢病预防与控制分会, 中华预防医学会健康传播分会. 中国肝癌一级预防专家共识(2018) [J]. 临床肝胆病杂志, 2018, 34(10): 2090-2097. DOI: 10.3969/j.issn.1001-5256.2018.10.008.
- [205] Chinese Society of Hepatology, Chinese Medical Association. The consensus of secondary prevention for primary liver cancer (2021 version) [J]. J Clin Hepatol, 2021, 37(3): 532-542. DOI: 10.3969/j.issn.1001-5256.2021.03.008.
- 中华医学会肝病学会. 原发性肝癌二级预防共识(2021年版)[J]. 临床肝胆病杂志, 2021, 37(3): 532-542. DOI: 10.3969/j.issn.1001-5256.2021.03.008.